|UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB                                                                                                                                                                                                                                                                   
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|                                                                                                                                                                                                                                                                                                                                                      
|                                                                                                                                                                                                                                                                                                                                                      
|(Mark One)                                                                                                                                                                                                                                                                                                                                            
|                                                                                                                                                                                                                                                                                                                                                      
|[X]                                                                                                                                                                                                                                                                                                                                                   
|                                                                                                                                                                                                                                                                                                                                                      
|[  ]                                                                                                                                                                                                                                                                                                                                                  
|                                                                                                                                                                                                                                                                                                                                                      
|Commission file number 0-26108                                                                                                                                                                                                                                                                                                                        
|                                                                                                                                                                                                                                                                                                                                                      
|NATUREWELL, INCORPORATED(Name of small business issuer in its charter)                                                                                                                                                                                                                                                                                
|                                                                                                                                                                                                                                                                                                                                                      
|Delaware(State or other jurisdiction
of incorporation or organization)                                                                                                                                                                                                                                                                                
|                                                                                                                                                                                                                                                                                                                                                      
|110 West C St., Suite 1300, San Diego, California 92101(Address of principal executive office)      (Zip Code)                                                                                                                                                                                                                                        
|                                                                                                                                                                                                                                                                                                                                                      
|Registrant's telephone number including area code:  (619) 234-0222                                                                                                                                                                                                                                                                                    
|                                                                                                                                                                                                                                                                                                                                                      
|Securities registered pursuant to Section 12(b) of the Act: None
(Title of Class)                                                                                                                                                                                                                                                                     
|                                                                                                                                                                                                                                                                                                                                                      
|Securities registered pursuant to Section 12(g) of the Act:Common Stock, $0.00001 Par Value
(Title of Class)                                                                                                                                                                                                                                          
|                                                                                                                                                                                                                                                                                                                                                      
|Check whether this issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes   [X]     No   [ ]
|                                                                                                                                                                                                                                                                                                                                                      
|Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation SB contained herein, and no disclosure will be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.  [X]    
|                                                                                                                                                                                                                                                                                                                                                      
|State the issuer's revenues for its most recent fiscal year:  $285,234.                                                                                                                                                                                                                                                                               
|                                                                                                                                                                                                                                                                                                                                                      
|State the aggregate market value of the voting stock held by non-affiliates computed by reference to the price at which the stock was sold, or the average bid and asked prices of such stock, as of a specified date within the past 60 days. As of October 5, 2007 the aggregate market value was $274,779.                                         
|                                                                                                                                                                                                                                                                                                                                                      
|State the number of shares outstanding of each of the issuer's classes of common equity, as of the last practicable date. As of October 5, 2007 the Company had issued and outstanding 682,809,052 shares of regular common stock and 19,000,000 shares of Series A Common Stock.                                                                     
|                                                                                                                                                                                                                                                                                                                                                      
|Documents incorporated by reference and parts of Form 10-KSB into which incorporated:  None.                                                                                                                                                                                                                                                          
|                                                                                                                                                                                                                                                                                                                                                      
|Transitional Small Business Disclosure Format (check one):  Yes   [ ]     No   [X]                                                                                                                                                                                                                                                                    

- 1 -



|
|





THIS REPORT ON FORM 10-KSB CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THE RESULTS DISCUSSED IN SUCH FORWARD-LOOKING STATEMENTS.



This report contains a number of forward-looking statements, which reflect the Company's current views with respect to future events and financial performance. Such forward-looking statements are based on management's beliefs and assumptions regarding information that is currently available, and are made pursuant to the "safe harbor" provisions of the federal securities laws. These forward-looking statements are subject to certain risks and uncertainties. The Company's actual performance and results could differ materially from those expressed in the forward-looking statements due to risks and uncertainties that could materially impact the Company in an adverse fashion and are only predictions of future results, and there can be no assurance that the Company's actual results will not materially differ from those anticipated in these forward-looking statements. In this report, the words "anticipates", "believes", "expects", "intends", "plans", "may", "future", and similar expressions identify forward-looking statements. Readers are cautioned to consider the risk factors described below and not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company has no obligation to publicly update or revise any of the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



ITEM 1.  DESCRIPTION OF BUSINESS

Background of Company

NatureWell, Incorporated (the "Company") is a public company traded on the Over-the-Counter Bulletin Board ("OTC-BB") under the symbol "NAWL." The Company is engaged in the research and development of unique proprietary healthcare products intended for a variety of conditions. Currently the Company's primary focus is on the distribution and sale of its migraine medication, MIGRASPRAY(R), a homeopathic over-the-counter drug used for the treatment and prevention of migraine headaches. The Company intends to exclusively market MIGRASPRAY to healthcare professionals, directly to consumers and to qualified independent pharmacies.



The Company outsources its manufacturing, warehousing and major distribution activities to third party vendors. Customer service, sales and administration are handled at the Company's headquarters in San Diego, California. The Company currently has eight employees.



Business Strategy

The Company believes that a strong need exists for a safe and effective over-the-counter drug for the treatment of migraine headaches and its strategy is to position MIGRASPRAY as a comprehensive first-line of defense for treating migraine headaches and for the distribution of MIGRASPRAY to lead the development of a distribution platform that can be used in the future to launch the Company's other products. The medication, a sublingual spray (sprayed under the tongue), can be used for prevention of migraines, as well as for the treatment of migraine headache attacks. If a migraine attack still occurs while MIGRASPRAY is being used preventatively, the medication may also be used to treat the acute attack. This comprehensive approach can be highly effective in dramatically reducing or eliminating migraines and represents a safe alternative to expensive prescription medications. In addition to its use as a migraine reliever or preventative, MIGRASPRAY may also be used for other types of headaches and pain, including headache pain and cramping associated with menstrual cycles and headaches due to hangover.



The Company plans to market MIGRASPRAY to healthcare providers using in-house and outside sales representatives and distributors and plans to also continue selling MIGRASPRAY via the Internet and other direct-to-consumer sales.



Order Fulfillment

The Company's order fulfillment process is outsourced to a third party vendor and the majority of its inventory is held at a third party warehouse. Order fulfillment activities include receiving merchandise from the warehouse, inspecting merchandise for damages or defects, packaging and processing customer orders and shipping the product. Each customer is generally charged a shipping and handling fee in addition to the cost of the product unless such fees have been waived as part of a sales promotion.

- 2 -



|
|





Product Development

During the evaluation phase of product development, the Company analyzes the suitability of a product for mass distribution, as well as the anticipated perceived value of the product to consumers; determines whether an adequate and timely supply of the product can be obtained; and further analyzes whether the estimated profitability of the product satisfies the Company's needs. The Company will review products and product concepts in the future in order to select those that it believes will be successful in one or more markets.



Product Overview

MIGRASPRAY

MIGRASPRAY is a patented, clinically tested, over-the-counter homeopathic drug for the fast relief and prevention of the symptoms of migraine headaches and is currently sold through a limited number of healthcare practitioners throughout the United States, as well as directly to consumers over the Internet and through telephone orders.



MIGRASPRAY is sprayed under the tongue (sublingual administration), which promotes enhanced bioavailability and rapid metabolization by directly entering the bloodstream through the mucous membrane, avoiding degradation from exposure to the gastrointestinal tract and liver. This fast acting delivery system allows MIGRASPRAY to provide rapid relief from migraine pain and other associated symptoms. It contains the active ingredients feverfew (its primary ingredient), polyporus, goldenseal and dandelion. Feverfew has been used for centuries for the treatment of a variety of ailments including headaches, rheumatic aches, abdominal pain and menstrual cramps. Studies have shown that feverfew acts as a natural anti-inflammatory controlling the inflammation that results in cerebral blood vessel dilation, believed to cause or contribute to the symptoms of migraine headaches. The active ingredients in feverfew are sesquiterpene lactones, the primary component being Parthenolide, a phyto-chemical. In limited doctor tests conducted on behalf of the Company, and consistent with large clinical studies indicating the effectiveness of feverfew for preventing migraines, MIGRASPRAY has been shown to be effective in dramatically reducing the frequency or eliminating migraine headaches entirely, when taken daily.



|* | Contains:             | 10 ml or 30 ml.                                                                                                                                                                                                                                            
|- | --------------------- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|* | Indication:           | For relief of headaches.                                                                                                                                                                                                                                   
|* | Directions:           | A 10 full spray dose is administered by applying 5 sprays under the tongue and holding for 30 seconds before swallowing and immediately repeating. Dose can be repeated every 5 minutes if required, up to 6 doses. Use as needed or directed by physician.
|* | Active
Ingredients:   | A proprietary homeopathic blend: feverfew (Pyrethrum Parthenium), Goldenseal (Hydrastis Canadensis), Dandelion (Taraxicum Officinale), Larch Agaric (Polyporus Officinalis (all 3x).                                                                       
|* | Inactive
Ingredients: | Distilled water, glycerin, ascorbic acid, potassium Sorbate (as preservative), disodium EDTA.                                                                                                                                                              

Migraine Market

Estimates indicate that as many as 32 million Americans suffer from migraine headaches and that approximately three quarters of those sufferers are women. More than half of all sufferers rely totally on non-prescription remedies, the same as nearly 10 years ago.



An estimated 150 million workdays or an equivalent of 1,200 million work hours are lost each year to head pain. Such lost productivity and employee absenteeism results in an estimated $13 billion in losses to employers each year.



A family of drugs known as "triptans," which constrict the cerebral blood vessels, dominate the prescription market for migraine remedies at costs reaching as high as $60 per dose. Triptans are sometimes contraindicated for patients with poor cardiac health and/or high blood pressure and patients are generally restricted in the amount of these drugs that may be used within a 30-day period due to potentially serious side effects.

- 3 -



|
|





The Company's Other Products

The Company has developed other products using its sublingual delivery system. All of these products are natural, fall within the category of either homeopathic drugs or dietary supplements and, thus, avoid the lengthy and expensive FDA approval processes. Sublingual (under the tongue) administration is a method of delivering substances into the body in a manner that promotes direct absorption through the highly vascularized mucous membrane under the tongue, rather than through the digestive tract, thereby bypassing exposure to the liver and gastric system. Sublingual administration of the Company's specially prepared sprays is a fast acting and efficacious delivery method, promoting enhanced bioavailability and rapid metabolization. Many of the spray formulations are intended to be symptomatically efficacious in a manner of minutes.



Though many sublingual substances are absorbed by diffusion (the sublingual area soaking up the substance), not all substances are permeable and accessible to the mucous membrane, which often functions as a barrier. However, using the Company's fine-particle spray sublingual administration, the sublingual mucous membrane can become an ideal site for rapid absorption.



The Company has developed the following products for future marketing and distribution:



ALLERSPRAY II (TM) - designed for the fast relief of allergy symptoms, without drowsiness, dry-mouth or other side effects. An estimated 58 million people suffer from allergies in the United States.



PMS SPRAY (TM) - intended to prevent and relieve the pain and symptoms of pre-menstrual syndrome. An estimated 40 million women suffer from PMS in the United States.



ARTHRISPRAY (TM) - intended to prevent and relieve the pain and symptoms of arthritis. An estimated 70 million people suffer from arthritis in the United States.



ANTI-OXY SPRAY (TM) - intended to reduce and prevent cerebral oxidative damage, which may be associated with Parkinson's disease. An estimated 1.5 million people suffer from Parkinson's disease in the United States.



Additionally, the Company has in various stages of development other products including, but not limited to, a natural sedative, a treatment for general aches and pains and other treatments for a variety of conditions.



Competition

The Company competes directly with many other companies, which generate revenue from direct marketing, wholesale/retail distribution, and electronic commerce activities. The Company also competes with a large number of consumer health product companies and retailers, which have substantially greater financial, marketing and other resources than the Company. Additionally, companies may attempt to imitate or "knockoff" the Company's products and may be able to take advantage of the product category awareness and product development, which the Company has created. The Company will seek to protect itself from "knockoffs" through the establishment and enforcement of its intellectual property and patent rights when appropriate and feasible.



Regulatory Compliance

Various aspects of the Company's business are subject to regulation and ongoing review by a variety of federal, state, local and foreign government agencies, including, but not limited to the Federal Trade Commission ("FTC"), the United States Post Office, the Consumer Product Safety Commission ("CPSC"), the Federal Communications Commission, ("FCC"), the Food and Drug Administration ("FDA"), various States' Attorneys General and other state, local consumer protection and health agencies. The statutes, rules and regulations applicable to the Company's operations, marketing and distribution are numerous, complex and subject to change.

If any significant actions were brought against the Company or any of its subsidiaries in connection with a breach of such laws or regulations, including, but not limited to the imposition of fines or other penalties, the Company could be materially and adversely affected. There can be no assurance that changes in the laws and regulations of any territory which forms a significant portion of the Company's market will not adversely affect the Company's business or results of operations.

- 4 -



|
|





The Company will collect and remit sales tax in states where it has a physical presence. Certain states in which the Company's only activity is direct marketing may attempt to require direct marketers, such as the Company, to collect and remit sales tax on sales to customers residing in such states. A 1995 United States Supreme Court decision held that Congress could legislate such a change. Thus far, Congress has taken no action to that effect. The Company will be prepared to collect sales taxes for other states if laws are passed requiring such collection. The Company does not believe that a change in the laws requiring the collecting of sales taxes will have a material adverse effect on the Company's financial condition or results of operations.



Trademarks and Patents

Proprietary protection for the Company's products, processes, and know-how is important to the Company's business. Thus, the Company plans to aggressively prosecute and defend its proprietary technology. The Company holds two patents and has one patent pending before the United States Patent and Trademark Office and intends to file additional patent applications, where appropriate, to protect technology, inventions and improvements that are considered important to the development of its business. The Company also relies upon trade secrets, know-how, and technological innovation to develop and maintain its competitive position.



Patent positions of healthcare product firms, including the Company's, are generally uncertain and involve complex legal and factual questions. Consequently, even though the Company may prosecute its patent applications with the United States and foreign patent offices, the Company does not know whether any applications will result in the issuance of patents or whether any issued patents will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States are maintained in secrecy until patents are issued, and publication of discoveries in the scientific or patent literature tend to lag behind actual discoveries, the Company cannot be certain that it was the original creator of inventions which may be covered by patent applications or that it was the first to file patent applications for such inventions.



There can be no assurance that a court of competent jurisdiction, if issued, would hold patents, valid. Moreover, to determine priority of invention, the Company may have to participate in interference proceedings declared by the United States Patent and Trademark Office or opposition proceedings before an equivalent foreign agency, which could result in substantial cost to the Company.



There can be no assurance that the patent applications, if any, will result in patents being issued or that if issued, the patents will afford protection against competitors with similar technology. Nor can there be any assurance that others will not obtain patents that the Company would need to license or circumvent.



The Company will also rely upon unpatented trade secrets, and there can be no assurance that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to the Company's trade secrets or disclose such technology, or that the Company can meaningfully protect its right to unpatented trade secrets.



Human Resources

The Company has eight employees. None of the Company's employees are covered by a collective bargaining agreement and the Company has experienced no work stoppages. The Company believes that it maintains positive relations with its personnel.



ITEM 2.  DESCRIPTION OF PROPERTY

The Company's corporate offices are located at 110 West "C" St, Suite 1300, San Diego, California 92101. The offices are approximately 872 square feet and are currently leased on a month to month basis at $3,820 per month.



ITEM 3.  LEGAL PROCEEDINGS

At June 30, 2007 the Company has a litigation reserve totaling $125,795 which it maintains for legal and settlement costs associated with its restructuring efforts and for litigation arising in the ordinary course of business. Notwithstanding the reserve established, in the light of the Company's current financial condition, the Company's cash liability, if any, arising from legal proceedings related to these matters, and others in which it is involved, could have a material adverse effect on the Company's financial position, results of operations or cash flows.



As discussed elsewhere in this Form 10-KSB, the Company is subject to regulation by a number of federal, state, and foreign agencies and is involved in various legal matters arising in the normal course of its business.

- 5 -



|
|





Currently the Company does not carry product liability insurance. The Company will evaluate the need for product liability insurance when sales volume warrants such an expenditure. There can be no assurance, however, that the Company can afford such insurance coverage or that such insurance coverage will be adequate to cover all losses, which the Company may incur in future periods or that coverage will be available for all of the types of claims the Company faces or may face.



In the opinion of management, the Company's liability, if any, arising from regulatory and legal proceedings related to these matters, and others in which it is involved, could have a material adverse effect on the Company's financial position, results of operations or cash flows.



ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None



PART II



ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

As of June 30, 2007, there were over 600 holders of record of the Common Stock. The Company has not paid cash dividends on its capital stock since inception and does not have any plans to do so in the future. The Company currently intends to retain earnings, if any, for use in its business.



Market Information

The Company's Common Stock is traded on the Over-the-Counter Bulletin Board ("OTC-BB") under the symbol "NAWL." The following table sets forth the high and low closing prices per share for the Company's Common Stock for the prior three years:



|                                      | HIGH   | LOW   
|------------------------------------- | ------ | ------
|Fiscal Year 2005:                     |        |       
|First Quarter                         | 0.0135 | 0.0046
|Second Quarter                        | 0.0055 | 0.0021
|Third Quarter                         | 0.01   | 0.0015
|Fourth Quarter                        | 0.005  | 0.003 
|                                      |        |       
|Fiscal Year 2006:                     |        |       
|First Quarter                         | 0.006  | 0.0016
|Second Quarter                        | 0.003  | 0.0008
|Third Quarter                         | 0.0031 | 0.0007
|Fourth Quarter                        | 0.002  | 0.001 
|                                      |        |       
|Fiscal Year 2007:                     |        |       
|First Quarter                         | 0.0011 | 0.0005
|Second Quarter (through Oct. 9, 2006) | 0.0006 | 0.0004

- 6 -



|
|





Recent Sales of Securities

During the year ending June 30, 2007 the Company made the following issuances and sales of securities in reliance upon the exemption provided by Section 4(2) of the Securities Act of 1933, as amended, Rule 506 of Regulation D hereunder.



In August 2006 the Company issued a promissory note to Dutchess Private Equities Fund ("Dutchess") in the amount of $201,500 (face value), which resulted in $155,000 of aggregate gross proceeds to the Company. Under the terms of the note, following an event of default the Holder has the right to switch the note into a convertible debenture which may then convert into common stock at a conversion price equal to the lesser of (i) seventy-five percent (75%) of the lowest closing bid price during the fifteen (15) trading days immediately preceding the Notice of Conversion for the portion of the Debenture being converted, or (ii) 100% of the lowest bid price for the twenty (20) trading days immediately preceding the Convertible Closing Date ("Fixed Conversion Price").



In August 2006 the company issued the following restricted shares of common stock; (i) 5,500,000 shares to employees for services rendered, (ii) 1,500,000shares for services rendered by an outside vendor, and (iii) 8,920,533 shares in exchange for convertible notes tendered for conversion having a value (including interest accrued thereon) of $22,251 at the time of conversion.



In August 2006 the company issued 1,705,839 restricted shares of regular common stock as partial payment of Incentive Shares due to Dutchess as required pursuant to the loan agreement underlying a note issued to Dutchess by the Company in the amount of $600,000 face value. The payment of Incentive Shares was valued at $6,823 by the Company (the Company has a contingent liability to issue an additional 332,355,689 Incentive Shares to Dutchess - see Note L to the Financial Statements).



In September 2006 the Company issued a promissory note to Dutchess in the amount of $403,000 (face value), which resulted in $310,000 of aggregate gross proceeds to the Company.  Under the terms of the note, following an event of default the Holder has the right to switch the note into a convertible debenture which may then convert into common stock at a conversion price equal to the lesser of (i) seventy-five percent (75%) of the lowest closing bid price during the fifteen (15) trading days immediately preceding the Notice of Conversion for the portion of the Debenture being converted, or (ii) 100% of the lowest bid price for the twenty (20) trading days immediately preceding the Convertible Closing Date ("Fixed Conversion Price").



In November 2006 the Company issued 5,000,000 restricted shares of common stock for $15,000 of services rendered by an outside vendor.



In December 2006 the Company issued 15,000,000 restricted shares of common stock for $45,000 of services rendered by an outside vendor.



In December 2006 the Company issued a promissory note to Dutchess in the amount of $572,000 (face value), which resulted in $400,000 of aggregate gross proceeds to the Company.  Under the terms of the note, following an event of default the Holder has the right to switch the note into a convertible debenture which may then convert into common stock at a conversion price equal to the lesser of (i) seventy-five percent (75%) of the lowest closing bid price during the fifteen (15) trading days immediately preceding the Notice of Conversion for the portion of the Debenture being converted, or (ii) 100% of the lowest bid price for the twenty (20) trading days immediately preceding the Convertible Closing Date ("Fixed Conversion Price").



In March 2007 the Company issued a promissory note to Dutchess in the amount of $429,000 (face value), which resulted in $300,000 of aggregate gross proceeds to the Company.  Under the terms of the note, following an event of default the Holder has the right to switch the note into a convertible debenture which may then convert into common stock at a conversion price equal to the lesser of (i) seventy-five percent (75%) of the lowest closing bid price during the fifteen (15) trading days immediately preceding the Notice of Conversion for the portion of the Debenture being converted, or (ii) 100% of the lowest bid price for the twenty (20) trading days immediately preceding the Convertible Closing Date ("Fixed Conversion Price").



In April 2006 the Company issued 16,000,000 restricted shares of common stock for $16,100 of services rendered by outside vendors.



In June 2007 the Company issued a promissory note to Dutchess in the amount of $143,000 (face value), which resulted in $100,000 of aggregate gross proceeds to the Company.  Under the terms of the note, following an event of default the Holder has the right to switch the note into a convertible debenture which may then convert into common stock at a conversion price equal to the lesser of (i) seventy-five percent (75%) of the lowest closing bid price during the fifteen (15) trading days immediately preceding the Notice of Conversion for the portion of the Debenture being converted, or (ii) 100% of the lowest bid price for the twenty (20) trading days immediately preceding the Convertible Closing Date ("Fixed Conversion Price").

- 7 -



|
|





RISK FACTORS



Certain statements under the headings "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Business," and elsewhere in this Report constitute "forward-looking statements" within the meaning of the rules and regulations promulgated by the Securities and Exchange Commission.



THIS REPORT ON FORM 10-KSB CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY FROM THE RESULTS DISCUSSED IN SUCH FORWARD-LOOKING STATEMENTS.



This report contains a number of forward-looking statements, which reflect the Company's current views with respect to future events and financial performance. Such forward-looking statements are based on management's beliefs and assumptions regarding information that is currently available, and are made pursuant to the "safe harbor" provisions of the federal securities laws. These forward-looking statements are subject to certain risks and uncertainties. The Company's actual performance and results could differ materially from those expressed in the forward-looking statements due to risks and uncertainties that could materially impact the Company in an adverse fashion and are only predictions of future results, and there can be no assurance that the Company's actual results will not materially differ from those anticipated in these forward-looking statements. In this report, the words "anticipates", "believes", "expects", "intends", "plans", "may", "future", and similar expressions identify forward-looking statements. Readers are cautioned to consider the risk factors described below and not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company has no obligation to publicly update or revise any of the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



As described above, the forward-looking statements contained in this report involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors include, but are not limited to the following: the Company's lack of operating history and the uncertainty of profitability; the Company's ability to obtain capital, which is critical to its future existence, and if able to obtain capital it can do so on terms that are advantageous or desirable to current shareholders and/or stakeholders of the Company, the Company's ability to successfully advertise or market its products to a degree necessary for it to drive product sales to a level necessary to reach profitability, the Company's ability to develop and introduce new products; the uncertainty of market acceptance of the Company's products and their market penetration; the uncertainties related to the Company's product development programs; the Company's future reliance on collaborative partners and licenses; the Company's future sales, marketing and distribution experience and dependence on distributors; the risks associated with obtaining governmental approval of the Company's products; the highly competitive industry in which the Company operates and the rapid pace of technological change within that industry; the uncertainty of patented and proprietary information protection and the Company's reliance on such patented and proprietary information; changes in or failure to comply with governmental regulation; the Company's dependence on key employees; and general economic and business conditions and other factors referenced in this report. Accordingly, any investment in the Company's common stock hereby involves a high degree of risk. In addition to the other information contained in this Form 10-KSB, the Company's business should be considered carefully before purchasing any of the securities of the Company. In addition to other information contained in this report, prospective investors should carefully consider the following factors before purchasing securities of the Company. Prospective investors are cautioned that the statements in this Section that are not descriptions of historical facts may be forward-looking statements that are subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those identified in "Risk Factors," "Business," and elsewhere in this report.



We Have a Limited Operating History and Have Incurred Operating Losses Since Inception. As a Result, We May Never Become Profitable.



We have a limited operating history upon which an investor can evaluate our potential for future success. We have generated an accumulated deficit of approximately $26.6 million through June 30, 2007. Although we commenced sales of our migraine product on a national level during the month of September 2001, sales have been limited to date. As a result, there is limited historical financial data upon which an investor can make an evaluation of our performance or make a decision regarding an investment in shares of its common stock.

- 8 -



|
|





Our business is subject to all the problems, expenses, delays, and risks inherent in the establishment of a new business enterprise, including but not limited to the following:

|● | limited capital;                                                                                                                               
|- | -----------------------------------------------------------------------------------------------------------------------------------------------
|● | delays in product development;                                                                                                                 
|● | possible cost overruns due to price increases in raw product;                                                                                  
|● | unforeseen difficulties in the Company's manufacturing processes;                                                                              
|● | risks associated with obtaining governmental approval or failing to comply with governmental regulation with respect to the Company's business;
|● | uncertain market acceptance; and                                                                                                               
|● | the absence of an operating history.                                                                                                           



Therefore, the Company may never achieve or maintain profitable operations and the Company may encounter unforeseen difficulties that may deplete its capital resources more rapidly than anticipated.



We May Be Unable To Manage Our Growth.



We plan to experience growth from the sale of our products. Such growth, if realized, could place a significant strain on the Company's management, financial, operating and technical resources. Failure to manage growth effectively could have a material adverse effect on the Company's financial condition or results of operations. Additionally, although the Company presently has no plans to acquire any "companies or assets of a material amount," should the Company decide to adopt acquisition plans as part of a future growth strategy, no assurance can be given that the Company can effectively integrate such acquired operations or assets with its own operations. The Company may also seek to finance any such future acquisition by debt financing or issuance of equity securities and there can be no assurance that any such financing will be available at acceptable terms or at all.

We Face Extensive Government Regulation.



The manufacturing, processing, formulating, packaging, labeling and advertising of the Company's products are subject to regulation by one or more federal agencies, including the United States Food and Drug Administration, the Federal Trade Commission and the Consumer Product Safety Commission. The Company's activities are also regulated by various state and local governmental agencies in the states where the Company distributes its products and in which the Company's products are sold. Although the Company believes that it is in compliance with all existing regulations, the Company remains subject to the risk that, in one or more of its present or future markets, its products or marketing systems could be found not to be in compliance with applicable laws or regulations.



In addition, the Company is unable to predict whether it will be able to comply with any new legislation or regulations or amendments to legislation and regulations that may be enacted in the future. New laws or regulations could require the reformulation of certain products to meet new standards, the recall or discontinuance of certain products not capable of reformulation, additional record keeping, expanded documentation of the properties of certain products, expanded or different labeling, and/or scientific substantiation. Failure by the Company to comply timely with all laws and regulations applicable to its products could have a material adverse effect on its business, operations, and financial condition.



We Do Not Carry Product Liability Insurance Even Though We Are Subject to Product Liability Claims.



The Company, like other retailers, distributors and manufacturers of products that are ingested, faces the inherent risk of exposure to product liability claims in the event that the use of its products results or is believed to result in injury. However, we currently do not carry product liability insurance. Pending the maturity of the Company's new marketing strategy, and sales volume that the Company determines warrants the need for insurance, coverage will be evaluated in amounts that management believes is adequate to cover the risks it faces in the industry in which it competes. There can be no assurance, however, that the Company can afford such insurance coverage or that such insurance coverage will be adequate to cover all losses, which the Company may incur in future periods or that coverage will be available for all of the types of claims the Company faces or may face. We cannot assure the safety or effectiveness of our products.

- 9 -



|
|





We Face Intense Competition From Competitors With Far Greater Market Share, Market Recognition, and Financial Resources.



The business of designing, marketing, and selling products for the treatment and/or prevention of migraine is highly competitive. Numerous manufacturers, distributors, and retailers compete actively for customers, including a number of international pharmaceutical companies with vast financial resources. Many of the Company's competitors are substantially larger than the Company and have greater market share, market recognition, and financial resources.



The prescription drug market for migraines is led by GlaxoSmithKline with Imitrex



A. PRESCRIPTION DRUGS

|I.  | Triptans:       
|--- | ----------------
|    |                 
|    | ●               
|    |                 
|    |                 
|    |                 
|    |                 
|    | ●               
|    |                 
|    | ●               
|    |                 
|    | ●               
|    |                 
|II. | Anticonvulsants:
|    |                 
|    | ●               
|    |                 

B. OVER-THE-COUNTER DRUGS

|I.  | Analgesics:                                       
|--- | --------------------------------------------------
|    |                                                   
|    | ●                                                 
|    |                                                   
|    | ●                                                 
|    |                                                   
|II. | NSAID's:                                          
|    |                                                   
|    | ●                                                 
|    |                                                   
|    | ●                                                 
|    |                                                   
|    |                                                   
|    |                                                   
|[A] | - Abortive treatment of migraine.                 
|[P] | - Prophylactic treatment of migraine (prevention).

The products listed above have resources placed behind marketing and product awareness campaigns that are far greater than the amount of resources available to the Company to support similar efforts for its migraine product. Additionally, such products are generally supported by substantial testing and scientific validation of their efficacy which may be viewed by consumers as superior to the limited data accumulated by the Company to support the efficacy of its migraine product.

- 10 -



|
|





The Company also competes with other manufacturers that market natural over-the-counter products for migraines. Typically these competitors are small private companies for which the Company has little data or information. The limited amount of data about such competitors and the market share that they control makes it very difficult to analyze which types of marketing efforts and initiatives have proven successful for these competitors. As such, the Company will have to engage in marketing efforts that are largely untested and speculative as to their effectiveness.



The market for other products that the Company would like to introduce in the future will also be very highly competitive and dominated by many of the same competitors and challenges that the Company faces for its migraine product. Because the Company's ability to reach profitability and remain competitive depends in part upon the successful introduction of new products, the challenges of competitors having vastly greater resources, market share, proven marketing techniques and products with demonstrated efficacy make the future success of the Company a difficult task, which there can be no assurance is achievable.



We Depend Upon A Single Product and a Limited Customer Base.



The Company has only one product that it is currently attempting to distribute nationally, a homeopathic drug called MIGRASPRAY which is used for the treatment and prevention of migraine headaches. The Company's sales depend exclusively on the MIGRASPRAY product, creating a risk of concentration associated with the sale of a single product and limited customer base. The loss of this single product market could cause severe damage to the Company's financial future. The Company has no customers that represent greater than 5% of gross revenues. As a result, the Company has no large customers upon which it can rely for sales of its product.



Sales of Our Migraine Relief Product, MIGRASPRAY, Have Been Limited Due To Our Limited Marketing Budget. As a Result, MIGRASPRAY May Never Gain Market Acceptance.



We are attempting to market our migraine relief product nationally. However, as a result of capital constraints, the national marketing of MIGRASPRAY has been very limited, and the Company has experienced minimal sales to date.



There can be no assurance that we will obtain the funds necessary to successfully market MIGRASPRAY. Even if we were to obtain the funds necessary to successfully market MIGRASPRAY, there is no assurance that sales of MIGRASPRAY would increase.



Our Ability to Generate Revenues Depends In Part Upon the Development Of New Products, Which May Never Materialize.

The Company is in various stages of development on a number of products. A substantial part of the Company's future growth strategy depends upon the development of new products. However, there can be no assurance that such new products will be developed timely and within budget or if developed will meet with market acceptance. Any new products developed by the Company likely will face competition from numerous larger manufacturers whose resources are substantially greater than those of the Company and whose market presence may make it difficult or uneconomic for the Company to introduce new products against such competition. The market for natural remedies, treatments and dietary supplements is highly sensitive to the introduction of new products that may rapidly capture a significant share of the market. As a result, the Company's ability to remain competitive depends in part upon the successful introduction of new products.



Inflation May Harm Our Financial Results.

Inflation affects the cost of raw materials, goods, and services we use. In recent years, inflation has been modest. If inflation were to increase, the competitive environment in the over the counter drug market limits our ability of the Company to recover higher costs resulting from inflation by raising prices of our products.



We Depend Upon Our Key Personnel.



The Company is dependent on the efforts and abilities of certain of its senior management, particularly James Arabia, its Chief Executive Officer. As an accommodation to the Company, much of key management (as well as the outside directors on the board of directors) in the past had accepted securities issued by the Company in lieu of cash compensation for their services, including Mr. Arabia. This allowed the Company to retain its key personnel. The interruption of the services of such key management (or outside directors) could have a material adverse effect on the Company's operations, profits and future development, if suitable replacements are not promptly obtained, and there can be no assurance that such key personnel would accept compensation other than cash for their services in the future if the Company again became unable to pay. In addition, the Company's success depends, in part, upon its ability to attract and retain other talented personnel. There can be no assurance that the Company will be able to attract and retain such personnel necessary for the development of the business of the Company.

- 11 -



|
|





We Have Limited Intellectual Property Rights. We May Not Be Able to Commercialize our Products Under Development If They Infringe Existing Patents or Patents That Have Not Yet Issued.



The Company's patents and trademarks are valuable assets, which are very important to the marketing and national distribution of its products. The Company holds trademarks for NatureWell, MigraSpray, Allerspray and MigraDaily and also holds two patents with the United States Patent and Trademark Office; "Therapeutic Nasal Spray Administered Composition Containing Feverfew" (patent # 6103218) and "Compositions and Methods for the Treatment of Aches and Pains" (patent # 6770263 B1). The Company intends to file additional patent applications, where appropriate, to protect technology, inventions and improvements that are considered important to the development of its business. The Company also relies upon trade secrets, know-how, continuing technological innovation, and licensing opportunities to develop and maintain its competitive position.



Consequently, even though the Company may pursue patent applications with the United States and foreign patent offices, the Company does not know whether any applications will result in the issuance of patents or whether any issued patents will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States are maintained in secrecy until patents are issued, and publication of discoveries in the scientific or patent literature tend to lag behind actual discoveries, the Company cannot be certain that it was the original creator of inventions which may be covered by patent application or that it was the first to file patent applications for such inventions.



There can be no assurance that a court of competent jurisdiction would hold the Company's patents valid. Moreover, to determine priority of invention, the Company may have to participate in interference proceedings declared by the United States Patent and Trademark Office ("PTO") or opposition proceedings before an equivalent foreign agency, which could result in substantial cost to the Company. There can be no assurance that the patent applications will result in patents being used or issued, nor that if issued, the patents will afford protection against competitors with similar technologies; nor can there be any assurance that others will not obtain patents that the Company would need to license or circumvent. The Company will also rely up on unpatented trade secrets, and there can be no assurance that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to the Company's rights in the unpatented trade secrets.



We May Not Be Able To Continue As a Going Concern.

In their report accompanying the audit of our June 30, 2007 financial statements, our auditors expressed doubt as to our ability to continue as a going concern. To date, the Company has had limited sales due to the early stage of its efforts to transition into the marketing and distribution of products. Prior to the first quarter of fiscal year ending June 30, 2002, the Company was primarily engaged in research and development activities. Consequently, the Company has incurred recurring losses from operations. These factors, as well as the risks associated with raising capital through the issuance of equity and/or debt securities creates uncertainty as to the Company's ability to continue as a going concern.

Assuming the completion of sufficient capital raising efforts, the Company believes that capital raised, together with cash generated from operations, will be sufficient to fund the operations of the Company for at least the next year. However, there can be no assurance that the Company will be able to complete these efforts or produce future revenues. To the extent that the proceeds from the capital raising efforts and cash flow from operations fall short or are insufficient to fund the Company's activities, we may not be able to continue as a going concern.

The Company's plans to address its going concern issues include:



|* | Increasing sales of its products through national distribution channels and through direct marketing to consumers;     
|- | -----------------------------------------------------------------------------------------------------------------------
|* | Raising capital through the sale of debt and/or equity securities; and,                                                
|* | Settling outstanding debts and accounts payable, when available, through the issuance of debt and/or equity securities.

We Require Significant Amounts of Additional Financing Which Could Result in Dilution to Investors; Additional Financing Could be Unavailable or Have Unfavorable Terms



The development and national distribution of the Company's products will require a substantial commitment of funds. We will be required to raise additional capital through equity and/or debt financing (including convertible debt). Any equity financings could result in dilution to our then-existing stockholders. Sources of debt financing may result in higher interest expense. Any financing, if available, may be on terms unfavorable to us. If such capital raising efforts are unsuccessful, we may be required to reduce or curtail operations and would unlikely to be able to continue as a going concern. The Company's actual capital requirements will depend on many factors, including, but not limited to, the cost and timing of product development and launch activities, the success of research and development efforts, the cost and timing of expansion of its sales and marketing activities, the progress of the Company's national distribution efforts and the commercialization efforts of the Company's competitors, the costs involved in acquiring, prosecuting, maintaining, enforcing and defending intellectual property rights, developments related to regulatory issues, and other factors.

- 12 -



|
|





Risk Factors Relation To Our Current Financing Arrangements:

We Are Delinquent In Payments To Our Unsecured Creditors And May Face Collection Actions As a Result.



The Company is delinquent with a number of unsecured creditors for which no payment arrangements exist or for which no agreement to forestall collection action has been agreed upon. At June 30, 2007 the Company has a litigation reserve totaling $125,795 which it maintains for legal and settlement costs associated with its restructuring efforts and for current litigation arising in the ordinary course of business. Notwithstanding the litigation reserve established, in the light of the Company's current financial condition, the Company's cash liability, if any, arising from legal proceedings, could have a material adverse effect on the Company's financial position, results of operations or cash flows. Unsecured creditors amount to approximately $152,000, excluding officers and directors, including those accounted for in the Company's litigation reserve of $125,795, and are comprised of a number of creditors owed amounts of less than $5,000. Whenever feasible the Company negotiates with these creditors to reach settlement agreements that are acceptable to the Company, however, if the Company is unable to reach acceptable settlement arrangements it may be subject to various collection actions.



We Have Secured Debt Obligations That are in Default



As of June 30, 2007, the Company was in payment default on the following secured notes; (i) six senior notes issued to Dutchess totaling $2,069,762, before aggregate original issue discounts of $278,299, including interest accrued thereon of $87,041, which accrue interest at the rate of 12%, (ii) five senior secured notes totaling $443,143, including interest thereon of $57,915 which accrue interest at the rate of between 4% and 8%, and (iii) subordinated secured notes totaling $1,662,384 including interest thereon of $498,796 which accrue interest at the rate of between 8% and 10%. All of the defaulted notes listed have either passed their original stated maturity or are entitled to accelerated payment of principal under the default provisions of such notes. None of the holders of the defaulted notes discussed herein have initiated any collection actions against the Company.



The Company has no scheduled repayment arrangements in regard to any of the defaulted debt listed above except in regard to $200,000 of the senior secured notes which are owned by the Company's Chief Executive Officer, James R. Arabia, pursuant to an agreement reached between the Company and Mr. Arabia on June 16, 2006 whereby the Company makes monthly payments against past due monies owed to Mr. Arabia, of which the $200,000 of senior notes is included in such past due monies owed (see also Note M to the Financial Statements - "Related Party Transactions" and Note N to the Financial Statements - "Commitments and Contingencies").

Because these creditors are secured by virtually all of the Company's assets, the Company could face action to have its assets foreclosed upon. Collection action by any secured creditor is governed by an Intercreditor Agreement between such creditors, which requires a majority of senior creditors to approve of any collection action by any secured creditor(s) before such action is commenced (including an action to foreclose on the Company's assets). Although the Company believes that the majority of senior creditors will not agree to authorize collection action at this time, there can be no assurance that the senior creditors will not authorize certain collection actions. If collection actions are authorized and do commence, the assets of the Company could be foreclosed upon and the Company's ability to continue as a going concern would be severely limited.



It is likely that the Company will need to negotiate debt for equity swaps with defaulted creditors, which could lead to the issuance of substantial amounts of common stock and substantial dilution of then-existing shareholders. There can be no assurance that any of the Company's secured creditors will accept equity in exchange for their debt. If the Company is unable to issue equity to retire much of its secured debt obligations, it may be very difficult to raise capital through the sale of debt or equity.

Risk Factors Relating to Our Common Stock:



We Do Not Expect to Pay Dividends for Some Time, if At All.



No cash dividends have been paid on our common stock. We expect that any income received from operations will be devoted to our future operations. We do not expect to pay cash dividends in the foreseeable future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors.



The Public Market for Our Common Stock is Volatile and Limited.



Our common stock is currently quoted on the Over the Counter Bulletin Board under the ticker symbol NAWL. The market price of the Company's common stock has been, and is likely to continue to be, volatile. Factors such as announcements of new products by the Company or its competitors, changes in pricing policies by the Company or its competitors, quarterly fluctuations in the Company's operating results, announcements relating to strategic relationships, government regulatory actions, general conditions in the market for healthcare products, overall market conditions and other factors may have a significant impact on the market price of the common stock. In addition, in recent years the stock market in general, and the shares of healthcare product companies have experienced extreme price fluctuations. This volatility has had a substantial effect on the market prices of securities issued by many companies for reasons unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of the Company's common stock.

- 13 -



|
|





In addition, the public float of the Company's common stock is small in comparison to total shares outstanding on a fully diluted basis, resulting in a very thin public market for the trading of the Company's shares. Limited trading volume entails a high degree of volatility in the stock price. In the 52-week period from July 1, 2006 to June 30, 2007, the closing price for the shares of the Company's stock on the OTC Bulletin Board ranged from $0.0007 to $0.006 This situation of limited liquidity and volatile stock price will most likely continue for the near future.



Our Common Stock is Subject to the "Penny Stock" Rules of the SEC and the Trading Market in Our Securities is Limited, Which Makes Transactions In Our Stock Cumbersome and May Reduce the Value of an Investment in Our Stock.



The Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a "penny stock," for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require:

|* | that a broker or dealer approve a person's account for transactions in penny stocks; and                                                                          
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------
|* | the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.



In order to approve a person's account for transactions in penny stocks, the broker or dealer must:

|* | obtain financial information and investment experience objectives of the person; and                                                                                                                                                                 
|- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|* | make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.



The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form:

|* | sets forth the basis on which the broker or dealer made the suitability determination; and                
|- | ----------------------------------------------------------------------------------------------------------
|* | that the broker or dealer received a signed, written agreement from the investor prior to the transaction.



Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

Rule 144 Stock Sales



As of June 30, 2007, the Company had approximately 117,424,415 shares of the Company's outstanding common stock as "restricted securities" which may be sold only in compliance with Rule 144 adopted under the Securities Act of 1933, as amended or other applicable exemptions from registration. Rule 144 provides that a person holding restricted securities for a period of one year may thereafter sell in brokerage transactions, an amount not exceeding in any three month period the greater of either (i) 1% of the Company's outstanding common stock, or (ii) the average weekly trading volume during a period of four calendar weeks immediately preceding any sale. Persons who are not affiliated with the Company and who have held their restricted securities for at least two years are not subject to the volume limitation. Potential or actual sales of the Company's common stock by present shareholders under Rule 144 may have a depressive effect on the price of the Company's stock.



ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS

The Company intends to exclusively market its MIGRASPRAY product to healthcare providers and directly to consumers, and has conducted limited test marketing for this marketing strategy. The Company manages all phases of direct and other marketing for its MIGRASPRAY product in the United States, which includes product selection and development, manufacturing by third parties, acquisition of media and advertising, design and production of marketing materials and creative, order processing and fulfillment, and customer service. The Company's ability to execute a business and marketing plan are dependent upon obtaining an adequate amount of working capital through its capital raising efforts.



PLAN OF OPERATION

- 14 -



|
|





EXPECTED CAPITAL REQUIREMENTS

Over the next twelve months the Company will need to raise substantial additional working capital to fund its business operations and execute its business plan.



EXPECTED RESEARCH AND DEVELOPMENT ACTIVITIES

The Company plans to continue research and development activities in the future. The Company has completed its research and development activities with respect to MIGRASPRAY, to the extent that such product is being marketed currently, and its initial research and development activities with respect to ALLERSPRAY II, PMS SPRAY, ARTHRISPRAY and ANTI-OXY SPRAY to the extent that such products can be produced and distributed in the future. The Company has been involved in research for the development of novel products, including, but not limited to, a natural sedative, a treatment for general aches and pains and other treatments for a variety of conditions, and plans to continue such research as is practicable. The Company plans to conduct clinical trials, doctor and laboratory tests and market analyses for such new products when appropriate and to continue clinical testing and analyzing certain existing products. The Company holds two patents and has one patent pending.

EXPECTED PURCHASES OR SALES OF PLANT AND SIGNIFICANT EQUIPMENT

The Company does not expect to purchase and/or sell any significant equipment during the next twelve months. However this does not preclude the Company from doing so if it is deemed necessary for the growth and success of the Company.



EXPECTED CHANGES IN NUMBER OF EMPLOYEES

The Company has added 5 employees as sales reps and expects to add additional employees over the next twelve months if it is successful in its securing capital adequate to expand its business. If any anticipated employee positions are to be filled they will likely be at the sales/customer service and operations level. The Company currently operates with eight employees.



RESULTS OF OPERATIONS

As discussed above, the Company did not engage in any significant business prior to April 17, 1995. During April 1995, the Company acquired Unified Technologies, Inc., a development stage business. Since that time, the Company has been developing various healthcare products and now intends to exclusively distribute its products to healthcare providers and directly to consumers.



FISCAL YEAR ENDED JUNE 30, 2007 COMPARED TO THE CORRESPONDING PERIOD IN 2006.



On a consolidated basis, the company had gross sales totaling $285,234 for the year ended June 30, 2007, compared with $51,402 in gross sales for the same period ending June 30, 2006. This represented an increase of $233,832 or 454.9% in gross sales from the year before. The sales increase is primarily attributable to increased sales and marketing efforts of the Company's product.



The Company experienced a net loss of $2,300,308 for the twelve-month period ended June 30, 2007, compared with a net loss of $787,282 for the same period ended June 30, 2006. This represents an increase of $1,513,026 or 192.2% from the prior year. The increase in net loss is primarily attributable to increased sales, administrative and marketing expense associated with the Company's increased sales and marketing efforts of its migraine product.



The Company had a gross profit margin for the year ended June 30, 2007 of 86.0% or $245,242. The Company's cost of products sold for the years ended June 30, 2007 and 2006 was $39,992 and $5,978, respectively. The Company expects product cost as a percentage of gross sales to remain stable from current levels.



Consulting fees totaled $212,000 for the year ended June 30, 2007, compared with $88,134 for the same period ending June 30, 2006. This represented an increase of $123,866 or 140.5% from the prior year. Marketing and advertising cost totaled $368,962 for the year ended June 30, 2007, compared to $22,546 for the same period ending June 30, 2006. Selling, general and administrative expenses incurred by the Company were $1,111,905 for the year ended June 30, 2007, compared with $588,272 for the same period ended June 30, 2006. This represented an increase of $523,633 or 89.0% from the prior year. The increase is due primarily to increased salaries, workforce and sales and marketing expenses.

- 15 -



|
|





FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

The Company has financed its operations primarily through the sale of promissory notes, revenue from sales and cash advances from its Chief Executive Officer, James R. Arabia. The Company anticipates that the proceeds from future sale of equity and/or debt securities (including convertible debt) together with revenues from product sales should be sufficient to finance its operations for the next twelve months. However, there can be no assurance that the Company will be successful in selling equity or securing debt financing, or that their will be sufficient sales or that any combination thereof will be sufficient to meet its capital needs, which, if not met, could result in the Company being unable to continue as a going concern. (See also "PLAN OF OPERATIONS")



At June 30, 2007 and 2006, the Company had current assets of $130,241 and $ 179,851 including cash of $18,536 and $151,724, respectively. At June 30, 2007, current assets included inventory valued at $71,050 and prepaid expenses of $31,492. At June 30, 2007 and 2006 the Company had total assets of $447,526 and $520,399, respectively including inventory reported as a long term asset valued at $ 271,123. The report of the Company's independent auditors on the financial statements for the year ended June 30, 2007, includes an explanatory paragraph relating to the uncertainty of the Company's ability to continue as a going concern due to recurring losses and the risks associated with raising capital through issuance of equity and/or debt securities.



Dutchess Private Equities Fund Investment Agreement



On March 31, 2006 the Company entered into an Investment Agreement with Dutchess Private Equities Fund, II, L.P. ("Dutchess"). Pursuant to the Agreement, Dutchess committed to purchase up to $10,000,000 of the Company's common stock over the course of 36 months in installments that may occur as frequently as every seven days (in the Company's discretion) and the Company obligated itself to file a registration statement with the Securities and Exchange Commission ("SEC") covering the shares of common stock underlying the Investment Agreement (2,000,000,000 shares) and to use its reasonable efforts to have the registration statement declared effective by the SEC.



On May 5, 2006 the SEC declared the Registration Statement effective (Registration No. 333-133528) for the shares underlying the Investment Agreement thereby entitling the Company to request that Dutchess purchase its common stock as outlined in the Agreement. The amount the Company may request from each purchase ("Puts"), shall be equal to, at its election, either (i) $150,000 or; (ii) 200% of the average daily volume (U.S. market only) ("ADV") of the Company's common stock for the ten (10) trading days prior to the applicable put notice date, multiplied by the average of the 3 daily closing bid prices immediately preceding the put date. The Company may tender a Put to Dutchess as often as once every 7 days and the put date shall be the date that Dutchess receives a put notice of a draw down by the Company. The purchase price shall be set at 95% of the lowest closing highest posted bid price of the common stock during the pricing period. The pricing period shall be the five (5) consecutive trading days immediately after the put date. As of June 30, 2007 the Company had tendered fifty (50) Puts to Dutchess, which in the aggregate, resulted in the sale of 414,140,994 shares of registered stock and net proceeds to the Company of $576,667.



In addition to its Put rights under the Investment Agreement, the Company also secured six loans from Dutchess in the form of promissory notes in the amount of $2,348,500 (face value), which resulted in $1,685,000 of aggregate net proceeds to the Company. Under the terms of the notes the Company must repay Dutchess in monthly installments in an amount equal to the greater of $186,949 per month or 100% of the proceeds of all Puts tendered to Dutchess within a thirty day period. The note is senior secured debt of the Company, equal in rank with all other senior secured debt, and is further secured by 50 Put notices that the Company executed and tendered to Dutchess as collateral for the note.



The Company will need to obtain additional working capital to fund its business operations through either the sale of equity to Dutchess under the Investment Agreement, additional working capital loans from Dutchess, the sale of equity or debt to other third parties or a combination thereof.



NEW ACCOUNTING STANDARDS

In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment of FASB Statement No. 115".  This statement permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. However, the amendment to SFAS No. 115 "Accounting for Certain Investments in Debt and Equity Securities" applies to all entities with available-for-sale and trading securities. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provision of SFAS No. 157, "Fair Value Measurements". The adoption of this statement is not expected to have a material effect on the Company's financial statements.

- 16 -



|
|





In September 2006, the SEC issued Staff Accounting Bulletin ("SAB") No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements." SAB No. 108 addresses how the effects of prior year uncorrected misstatements should be considered when quantifying misstatements in current year financial statements. SAB No. 108 requires companies to quantify misstatements using a balance sheet and income statement approach and to evaluate whether either approach results in quantifying an error that is material in light of relevant quantitative and qualitative factors. SAB No. 108 is effective for fiscal years ending after November 15, 2006. The Company does not expect that adoption of SAB No. 108 will have a material effect on its financial statements.



In September 2006, the FASB issued SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans - an amendment of FASB Statements No. 87, 88, 106, and 132(R)". This statement requires employers to recognize the overfunded or underfunded status of a defined benefit postretirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income of a business entity or changes in unrestricted net assets of a not-for-profit organization.  This statement also requires an employer to measure the funded status of a plan as of the date of its year-end statement of financial position, with limited exceptions. The provisions of SFAS No. 158 are effective for employers with publicly traded equity securities as of the end of the fiscal year ending after December 15, 2006. The Company currently has no such employee plans and does not expect to ever institute such plans.  The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.



In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". The objective of SFAS 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements.  SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.



In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statements No. 109". FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a two-step method of first evaluating whether a tax position has met a more likely than not recognition threshold and second, measuring that tax position to determine the amount of benefit to be recognized in the financial statements. FIN 48 provides guidance on the presentation of such positions within a classified statement of financial position as well as on derecognition, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.



INFLATION

Inflation may affect the cost of raw materials, goods, and services used by the Company. In recent years, inflation has been modest. The competitive environment in the over the counter drug market somewhat limits the ability of the Company to recover higher costs resulting from inflation by raising prices to its customers. Overall, product prices have generally been stable, and the Company seeks to mitigate the adverse effects of inflation primarily through improved productivity and cost containment programs. The Company does not believe that inflation has had a material impact on its results of operations for the periods presented.

- 17 -



|
|





ITEM 7.   FINANCIAL STATEMENTS



|INDEX TO FINANCIAL STATEMENTS   
|--------------------------------
|                                
|                                
|REPORT OF INDEPENDENT ACCOUNTANT
|                                
|FINANCIAL STATEMENTS:           
|                                
|                                
|                                
|                                
|                                
|                                
|                                
|                                
|                                
|                                

- 18 -



|
|





PART I
ITEM 1.FINANCIAL STATEMENTS

Chang G. Park, CPA, Ph. D.







Report of Independent Registered Public Accounting Firm



To the Board of Directors of
Naturewell, Incorporated and subsidiaries

We have audited the accompanying consolidated balance sheets of Naturewell, Incorporated and subsidiaries (the "Company") as of June 30, 2007 and 2006 and the related consolidated statements of operations, changes in shareholders' equity and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.



We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.



In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Naturewell, Incorporated and subsidiaries as of June 30, 2007 and 2006, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

The financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note Q to the consolidated financial statements, the Company's losses from operations raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.



/s/

October 11, 2007

Chula Vista, CA  91910



Member of the California Society of Certified Public Accountants
Registered with the Public Company Accounting Oversight Board

- 19 -



|
|







|NATUREWELL, INCORPORATED AND SUBSIDIARIES
|-----------------------------------------
|Consolidated Balance Sheets              
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|ASSETS                                   
|                                         
|Current Assets                           
|                                         
|                                         
|                                         
|                                         
|                                         
|Total Current Assets                     
|                                         
|Net Property & Equipment                 
|                                         
|Other Assets                             
|                                         
|                                         
|                                         
|Total Other Assets                       
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|LIABILITIES & STOCKHOLDERS' DEFECIT      
|                                         
|Current Liabilities                      
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|Total Current Liabilities                
|                                         
|Long-Term Liabilities                    
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|Total Long-Term Liabilities              
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|Stockholders' Deficit                    
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|                                         
|Total Stockholders' Deficit              
|                                         
|                                         
|                                         
|                                         
|                                         



See Notes to Consolidated Financial Statements.

- 20 -



|
|







|NATUREWELL, INCORPORATED AND SUBSIDIARIES            
|-----------------------------------------------------
|Consolidated Statements of Operations                
|For the Years Ending June 30, 2007 and 2006          
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|Revenues                                             
|                                                     
|                                                     
|Net Sales                                            
|                                                     
|Costs and Expenses                                   
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|Total Costs and Expenses                             
|                                                     
|                                                     
|Loss From Operations                                 
|                                                     
|Other Income & (Expenses)                            
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|Total Other Income & (Expenses)                      
|                                                     
|                                                     
|Net Income (Loss) Before Taxes                       
|                                                     
|                                                     
|                                                     
|                                                     
|Net Income (Loss)                                    
|                                                     
|                                                     
|                                                     
|                                                     
|                                                     
|Basic earnings (loss) per share                      
|                                                     
|                                                     
|                                                     
|                                                     
|Weighted average number of 
common shares outstanding



See Notes to Consolidated Financial Statements.

- 21 -



|
|







|NATUREWELL  INCORPORATED  AND SUBSIDIARIES               
|---------------------------------------------------------
|Consolidated Statement of Changes in Stockholders' Equity
|For the Years Ended  June  30, 2007 and  2006            
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         
|                                                         



See Notes to Consolidated Financial Statements.

- 22 -



|
|







|NATUREWELL, INCORPORATED AND SUBSIDIARIES                                   |                                                    
|--------------------------------------------------------------------------- | ---------------------------------------------------
|Consolidated Statements of Cash Flows                                       |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            | June 30,
2007                                      
|                                                                           
|                                                                            |                                                    
|                                                                            |                                                    
|CASH FLOWS FROM OPERATING ACTIVITIES                                        |                                                    
|Net income (loss)                                                           | $                                                  
|Adjustments to reconcile net loss to net cash used in operating activities: |                                                    
|                                                                            | Allowance doubtful accounts                        
|                                                                            | Depreciation and amortization                      
|                                                                            | Accrued  interest income                           
|                                                                            | Debt forgivnes                                     
|                                                                            | Amortization of debt discount                      
|                                                                            | Accrued interest expense                           
|                                                                            | Issunace of notes for accounts payable             
|                                                                            | Stock issued for services                          
|Changes in assets and liabilities:                                          |                                                    
|                                                                            | (Increase) decrease in accounts receivable         
|                                                                            | (Increase) decrease in inventory                   
|                                                                            | (Increase) decrease in prepaid expenses            
|                                                                            | Increase (decrease) in due to officers             
|                                                                            | Increase (decrease) in accrued expenses            
|                                                                            | Increase (decrease) inaccured litigation costs     
|                                                                            | Increase (decrease) in accounts payable            
|                                                                            |                                                    
|                                                                            | Net cash provided by (used in) operating activities
|                                                                            |                                                    
|CASH FLOWS FROM INVESTING ACTIVITIES                                        |                                                    
|                                                                            |                                                    
|                                                                            | Capital expenditure for property and equipment     
|                                                                            | (Increase) decrease in deposits                    
|                                                                            |                                                    
|                                                                            | Net cash provided by (used in) investing activities
|                                                                            |                                                    
|CASH FLOWS FROM FINANCING ACTIVITIES                                        |                                                    
|                                                                            | Finders Fee Paid                                   
|                                                                            | Stock conversion of notes payable                  
|                                                                            | Stock issued for cash                              
|                                                                            | Payments made on loans payable                     
|                                                                            | Proceeds from loans payable                        
|                                                                            |                                                    
|                                                                            | Net cash provided by (used in) financing activities
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            | Net increase (decrease) in cash                    
|                                                                            |                                                    
|                                                                            | Cash at beginning of period                        
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            | Cash at end of period                              
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|SUPPLEMENTAL DISCLOSURES OF 
CASH FLOW INFORMATION:                         |                                                    
|                                                                           
|                                                                            |                                                    
|Income taxes paid                                                           | $                                                  
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|Interest paid                                                               | $                                                  
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|NON-CASH ACTIVITIES                                                         |                                                    
|                                                                            |                                                    
|Note receivable officers                                                    | $                                                  
|Stock issued from conversion of convertible notes                           | 22,251                                             
|Stock issued for services                                                   |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    
|Total non-cash activities                                                   | $                                                  
|                                                                            |                                                    
|                                                                            |                                                    
|                                                                            |                                                    



See Notes to Consolidated Financial Statements.

- 23 -



|
|





NATUREWELL, INCORPORATED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDING JUNE 30, 2007 AND 2006





A.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

ORGANIZATION AND BASIS OF CONSOLIDATION:

NatureWell, Inc., a California corporation ("NWI-CA") was originally incorporated on April 26, 1983 (through an earlier predecessor corporation). In August 1998, NWI-CA acquired the assets and technology of Amtech Scientific, Inc. ("ATS") of which the assets were contributed to a newly formed subsidiary of NWI-CA, DiagnosTech, Inc, a California corporation ("DTI"). In September 2001, NWI-CA formed a wholly owned subsidiary in Delaware, NatureWell, Incorporated. This wholly owned subsidiary was established for the sole purpose of reincorporating NWI-CA in Delaware. In October 2001, NWI-CA obtained approval from a vote of a majority of its shareholders to reincorporate in Delaware. On October 25, 2001, the merger of NWI-CA into NatureWell, Incorporated, a Delaware corporation ("NatureWell", "NWI" or the "Company") was consummated. NWI-CA has been "merged-out" and dissolved as a result of the reincorporation. The Company has two wholly owned subsidiaries, Unified Technologies, Inc., a California corporation ("UTI") and Chemical Dependency Healthcare of California, Inc., a California corporation ("CDHC"). The Company as of June 30, 2007 also holds a 91.9 percent (91.9%) ownership interest in Nasal Mist, Inc., a California corporation ("NMI").



PRINCIPLES OF CONSOLIDATION:



The consolidated financial statements include the accounts of the Company and its subsidiaries and present them as one economic entity. All significant intercompany transactions and balances have been eliminated in consolidation as of June 30, 2007 and 2006.



BASIS OF ACCOUNTING:



The Company's policy is to use the accrual method of accounting to prepare and present financial statements, which conforms to generally accepted accounting principles ("GAAP').



REVENUE RECOGNITION AND TRADE SPENDING:



The Company recognizes revenue when the following conditions are met, (i) a customer has either paid or made arrangements to pay for the product, (ii) delivery to the customer has been made, (iii) the sale has been made at a fixed price or at a price that is determinable, (iv) collectibility is reasonably assured, (v) title and risk of loss has passed from the Company to the customer, and (vi) the buyer either does not possess any right to return the product and/or there no longer exists any substantial risk of return.



In the case of consigned product ("consigned product" having the broadest meaning as articulated in SAB-101) the Company's policy is that it does not recognize revenue, if any, until (i) title and risk of loss has passed from the Company to the buyer, (ii) the product has been paid for, and (iii) there no longer exists any substantial risk of return.



Notwithstanding the foregoing, the Company may in its discretion voluntarily decide to accept requests for product returns from its customers.



INVENTORY:



Inventory consists of healthcare and nutraceutical products. Inventory is valued at the lower of (i) cost or (ii) market based on conservatism. Cost is determined under the first-in, first-out (FIFO) method.



The Company has inventory that carries expiration dates ranging from June of 2003 to October of 2003, however, under the FDA, Homeopathic Drugs are not required to have an expiration date and such product has not, in actuality, expired. Therefore, the Company re-labels its inventory prior to sale and adds the cost of re-labeling to the cost basis of its inventory. The Company in the future intends to either omit the labeling of an expiration date or extend the labeling of an expiration date from the previous practice of two years.



Inventory has been allocated between short term assets and long terms assets to reflect the fact that it is uncertain that all of the Company's inventory will be disposed of within one year. The allocation reflects current sales trends estimates and does not take into consideration a completion of the Company's restructuring/capital raising efforts, which would presumably lead to increased sales of inventory within one year. Therefore, inventory currently classified as a long term asset, or some portion of it, may be disposed of within one year if sales accelerate from current levels.

- 24 -



|
|





MARKETING AND ADVERTISING COSTS



Marketing and advertising costs for the years ending June 30, 2007 and 2006 of $368,962 and $ 22,546, respectively, were charged to operations when incurred.



PROPERTY AND EQUIPMENT:



Property and equipment is recorded at cost. Maintenance, repairs, and minor renewals are expensed as incurred. When property and equipment are retired or otherwise disposed, the related cost and accumulated depreciation are eliminated and any gain or loss on disposition is reflected in current operations. Depreciation is accounted for on the straight-line method over the estimated useful lives of the assets, which ranges generally from three to five years. Property and equipment is shown net of accumulated depreciation of $8,011 and $7,032 for the years ended June 30, 2007 and 2006, respectively.



INCOME TAXES:



Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily to differences between the basis of various assets for financial and income tax reporting. The deferred tax asset represents the future tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred taxes are recognized for net-operating losses that are available to offset future taxable income and tax credits available to offset future income taxes. A valuation allowance is provided against the deferred tax asset, where realization is uncertain.



USE OF ESTIMATES:



The preparation of the Company's financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statement date and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates made by management.



SUMMARY OF SIGNIFICANT ACCOUNTING PRONOUNCEMENTS:



In February 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities - Including an Amendment of FASB Statement No. 115".  This statement permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. However, the amendment to SFAS No. 115 "Accounting for Certain Investments in Debt and Equity Securities" applies to all entities with available-for-sale and trading securities. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provision of SFAS No. 157, "Fair Value Measurements". The adoption of this statement is not expected to have a material effect on the Company's financial statements.



In September 2006, the SEC issued Staff Accounting Bulletin ("SAB") No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements." SAB No. 108 addresses how the effects of prior year uncorrected misstatements should be considered when quantifying misstatements in current year financial statements. SAB No. 108 requires companies to quantify misstatements using a balance sheet and income statement approach and to evaluate whether either approach results in quantifying an error that is material in light of relevant quantitative and qualitative factors. SAB No. 108 is effective for fiscal years ending after November 15, 2006. The Company does not expect that adoption of SAB No. 108 will have a material effect on its financial statements.



In September 2006, the FASB issued SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans - an amendment of FASB Statements No. 87, 88, 106, and 132(R)". This statement requires employers to recognize the overfunded or underfunded status of a defined benefit postretirement plan (other than a multiemployer plan) as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur through comprehensive income of a business entity or changes in unrestricted net assets of a not-for-profit organization.  This statement also requires an employer to measure the funded status of a plan as of the date of its year-end statement of financial position, with limited exceptions. The provisions of SFAS No. 158 are effective for employers with publicly traded equity securities as of the end of the fiscal year ending after December 15, 2006. The Company currently has no such employee plans and does not expect to ever institute such plans.  The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.

- 25 -



|
|





In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". The objective of SFAS 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements.  SFAS 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.



In June 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statements No. 109". FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a two-step method of first evaluating whether a tax position has met a more likely than not recognition threshold and second, measuring that tax position to determine the amount of benefit to be recognized in the financial statements. FIN 48 provides guidance on the presentation of such positions within a classified statement of financial position as well as on derecognition, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.



B.  FORMATION OF SUBSIDIARIES:



NASAL MIST, INC.



During August 1997, the Company formed Nasal Mist, Inc. (NMI), a subsidiary organized for the production and marketing of herbal nasal sprays. NMI received approximately $300,000 through a private placement. Pursuant to the private placement, the Company granted NMI a license and rights to receive from the Company and its successors-in-interest, an amount equal to 10% of the net sales, less commissions and discounts of nasal sprays sold. NMI is dormant, not engaged in any business operations and the Company does not intend to engage in any business operations at NMI in the future.



In July of 2002 the Company offered to purchase all outstanding shares of Nasal Mist, Inc. ("NMI") for three shares of the Company's stock for each share of NMI. The Company acquired 149,392 shares of NMI as a result of the offer and at the conclusion of the transaction had increased its ownership of NMI from 72.61% to 91.9%. The acquisition of the NMI stock was accounted for as the acquisition of additional interest in subsidiary resulting in an increase in goodwill for the amount of the fair market value of the shares issued to acquire the NMI stock ($31,372), and then the Company simultaneously wrote-off such goodwill as the Company values the NMI shares at zero.



NMI is dormant and not engaged in any operating activities and there are no plans to engage in any activities in the future.



C.  INVENTORY:



Inventory as of June 30, 2007 and 2006 is comprised of the following:





|                    | 2007        | 2006       
|------------------- | ----------- | -----------
|                    |             |            
|Healthcare Products | $    71,050 | $    14,115
|Healthcare Products | 271,123     | 331,123    
|                    |             |            
|                    | $   342,173 | $   345,238
|                    |             |            
|                    |             |            
|                    |             |            



Inventory consists of healthcare and nutraceutical products. Inventory is valued at the lower of (i) cost or (ii) market based on conservatism. Cost is determined under the first-in, first-out (FIFO) method.



The Company has inventory that carries expiration dates ranging from June of 2003 to October of 2003, however, under the FDA, Homeopathic Drugs are not required to have an expiration date and such product has not, in actuality, expired. Therefore, the Company re-labels its inventory prior to sale and adds the cost of re-labeling to the cost basis of its inventory. The Company in the future intends to either omit the labeling of an expiration date or extend the labeling of an expiration date from the current practice of two years.

Inventory has been allocated between short term assets and long terms assets to reflect the fact that it is uncertain that all of the Company's inventory will be disposed of within one year. The allocation reflects current sales trends and does not take into consideration successful capital raising efforts on the part of the Company, which would presumably lead to increased sales of inventory within one year. Therefore, inventory currently classified as a long term asset, or some portion of it, may be disposed of within one year if sales accelerate from current levels.

- 26 -



|
|





D.  BASIC AND FULLY DILUTED LOSS PER COMMON SHARE:



Effective November 30, 1998, the Company adopted the provisions of Statement of Financial Accounting Standards No. 128, Earnings per Share ("SFAS 128") which replaced the presentation of "primary" and "fully-diluted" earnings (loss) per common share required under previously promulgated accounting standards with the presentation of "basic" and "diluted" earnings (loss) per common share.



Basic earnings (loss) per common share is calculated by dividing net income or loss by the weighted average number of common shares outstanding during the period. The calculation of diluted earnings (loss) per common share is similar to that of basic earnings (loss) per common share, except that the numerator and denominator are adjusted to reflect the decrease in earnings per share or the increase in loss per share that could occur if securities or other contracts to issue common stock, such as stock options and convertible notes, were exercised or converted into common stock.



The Company was required to compute primary and diluted loss per share amounts for 2007 and 2006 pursuant to SFAS 128. Since the Company and its subsidiaries had losses applicable to common stock, the assumed effects of the exercise of outstanding warrants and stock options were anti-dilutive and, accordingly, dilutive per share amounts are the same as basic earnings (loss) per share.



E.  WARRANTS, OPTIONS AND STOCK BASED COMPENSATION:



Warrants and options outstanding as of June 30, 2007 and 2006 consists of 250,000 and 250,000, non-redeemable warrants and options to purchase shares of common stock of the Company, which are exercisable into 1 share of common stock at $0.05 per share and expire on October 1, 2007.



In May of 2004 the Company adopted its 2004 Incentive Stock Bonus and Option Plan (the "Plan"). The Plan is intended to advance the interests of the Company by affording to selected employees, directors and consultants, an opportunity for investment in the Company and the incentives inherent in stock ownership in the Company and to provide the Company with a means of attracting, compensating, and retaining the services of selected employees, directors and consultants. It initially allowed for the issuance of 10,000,000 shares of S-8 stock, subject to the board's authority to amend the Plan.



On December 21, 2005 the Plan was amended to allow for the issuance of up to 30,000,000 shares of S-8 stock. In addition to the shares authorized by the Plan, the Company may issue restricted shares, or securities that convert into restricted common stock (including convertible notes), to non-employees, employees, directors and consultants for services. Shares issued to non-employees, employees and directors in return for services are valued under the fair value method in accordance with SFAS 123. At June 30, 2007 18,642,742 shares were issued under the Plan.



Total compensation cost recognized in income for stock-based employee compensation was $ 5,500 (including officers) and $39,581 for the years ending June 30, 2007 and June 30, 2006 respectively. Of the $5,500 for June 30, 2007, $2,500 was for payment to an officer and $3,000 was for payment to a non-officer employee. Of the $39,581 for June 30, 2006, $30,000 was for payment to officers and $9,581 was for payment to non-officer employees. Total cost recognized in income for shares issued to non-employees for services rendered was $87,923 and $30,428 for the years ending June 30, 2007 and June 30, 2006 respectively.



F.  PREFERRED STOCK:



The Company has outstanding 75 shares, $1,000 liquidation preference, of Series C Convertible Preferred Stock. Pursuant to the terms of the Series C Convertible Preferred stock, owned by James R. Arabia, Chairman, President, And Chief Executive Officer of the Company, Mr. Arabia is allowed to cast a vote, on all matters that the Company's shareholders are permitted to vote upon, equal to .7% of all outstanding securities that are eligible to vote at the time of such shareholder action for each share of Series C Convertible Preferred that he owns (.7% X 75 shares = 52.5% of total vote). The shares convert into 1,875,000 shares of the Company's common stock and are non-transferable without the consent of the board of directors.



G.  SERIES A COMMON STOCK



The Company has 20,000,000 authorized shares of Series A Common Stock of which 19,000,000 shares are issued and outstanding. Of that amount, 10,000,000 are owned by the Company's Chief Executive officer, James R. Arabia, and 9,000,000 are owned by a partnership for which Mr. Arabia is the General Partner whereby he has sole voting and investment authority in regard to the 10,000,000 shares.

- 27 -



|
|





Each share of Series A Common Stock shall entitle the holder to cast ten (10) votes for all matters presented to the shareholders for vote, and each share may be converted at the option of the holder into one share of regular Common Stock by surrendering to the Company the certificate or certificates evidencing the shares of Series A Common Stock to be converted together with a written request that the shares be so converted. Holders of regular Common Stock and Series A Common Stock shall vote together as a single class on all matters as to which holders of the class of common stock are entitled to vote, except as may be otherwise required by law.



At June 30, 2007 the 19,000,000 shares of Series A Common Stock was eligible to cast a vote equal 23.9% of the eligible votes possessed by the common stock as a class (190,000,000 votes of an eligible 793,933,318 votes).



H.  LOANS PAYABLE AND CURRENT PORTION OF LONG TERM DEBT:



Loans payable as of June 30, 2007 and 2006 consist of the following:





|                                                                                                                                                    | 2007           | 2006           
|--------------------------------------------------------------------------------------------------------------------------------------------------- | -------------- | ---------------
|                                                                                                                                                    |                |                
|Loans payable with annual interest varying from 8 to 10% (net of debt discount of  $185,600 and $91,667 as of June 30, 2007 and 2006, respectively) | $    4,055,482 | $     2,474,536
|Current Portion of Long Term Notes Payable :                                                                                                        | -              | 0              
|                                                                                                                                                    |                |                
|                                                                                                                                                    | $    4,055,482 | $    2,474,536 
|                                                                                                                                                    |                |                
|                                                                                                                                                    |                |                
|                                                                                                                                                    |                |                



|(1) | Six promissory notes due to Dutchess Private Equities Fund, LP ("Dutchess") totaling $2,060,483 before aggregate original issue discounts of $185,600 as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|--- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|    | (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | (d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | (e)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | (f)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
|    | Under the terms of the six notes the Company must repay Dutchess in minimum monthly installments of $186,949 and the notes are senior secured debt of the Company, equal in rank with all other senior secured debt. The Company has been unable to make the full monthly payments pursuant to the terms of the notes since June of 2006. Dutchess has not initiated any collection action against the Company and has not exercised or given notice of its intent to exercise any remedies available to them under the terms of the notes. Pursuant to an arrangement between Dutchess and the Company, 100% of any proceeds derived from Puts that the Company delivers to Dutchess under its Equity Line of Credit shall be applied against the six notes until such notes are brought current (see Note O - "Restructuring").
|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|(2) | Notes that are in payment default are as follows; (i) two unsecured notes totaling $75,072, including interest thereon of $17,120 which accrue interest at the rate of 8% per annum, (ii) five senior secured notes totaling $443,143 including interest thereon of $57,915 which accrue interest at the rate of between 4% and 8%, and (iii) subordinated secured notes totaling $1,662,384 including interest thereon of $498,796 which accrue interest at the rate of between 8% and 10%. All of the five senior secured defaulted notes listed above have either passed their original stated maturity or are entitled to accelerated payment of principal under the default provisions of such notes. None of the holders of the defaulted notes discussed herein have initiated any collection actions against the Company.



The Company has no scheduled repayment arrangements in regard to any of the defaulted debt listed above except in regard to $216,441 ($200,000 face value) of the senior secured notes which are owned by the Company's Chief Executive Officer, James R. Arabia. Pursuant to an agreement reached between the Company and Mr. Arabia on June 16, 2006 the Company makes monthly payments against past due monies owed to Mr. Arabia, of which the $200,000 face value of senior notes is included in such past due monies owed (see also Note K to the Financial Statements - "Related Party Transactions" and Note L to the Financial Statements - "Commitments and Contingencies").



I.  LEASES:



The Company leases its corporate office facilities under a Month to Month lease that expires on March 1, 2008. The Company's base rent under the lease is $3,820 throughout the term of the lease.  Office rent and incidental expense was $54,324 and $38,139 for the years ending June 30, 2007 and 2006, respectively.



- 28 -



|
|





J.  NOTES PAYABLE AND LONG TERM PAYABLES:



Notes payable as of June 30, 2007 and June 30, 2006 consist of the following:



|                                                                             | June 2007  |  | June 2006  
|---------------------------------------------------------------------------- | ---------- |  | -----------
|                                                                             |            |  |            
|Senior Secured Notes, with annual interest of 8%                             | 142,701    |  | 131,834    
|Unsecured Convertible Notes, with annual interest of 4%                      | 41,569     |  | 62,040     
|Subordinated Secured Convertible Notes, with annual interest of 8%           | 35,218     |  | 32,536     
|Senior Secured Convertible Notes, with annual interest varying from 4% to 8% | 1,259,224  |  | 1,205,602  
|                                                                             |            |  |            
|                                                                             | $1,478,712 |  | $ 1,432,012
|                                                                             |            |  |            
|                                                                             |            |  |            
|                                                                             |            |  |            



The senior secured notes totaling $142,701 include interest accrued thereon of $11,984. The notes are secured by a first priority security interest in essentially all of the Company's assets, are equal in rank with other senior debt and accrue interest at 8% until maturity on October 1, 2008.



The unsecured convertible notes totaling $41,569 include interest accrued thereon of $3,444 and are convertible, in the aggregate, into 15,556,071 shares of common stock at the option of the holder.



The subordinated secured convertible notes totaling $35,218 include interest accrued thereon of $9,473. The notes are secured by a subordinate security interest (subordinated to senior debt) in essentially all of the Company's assets, are equal in rank with other subordinate secured debt, accrue interest at the rate of 8% per annum until October 1, 2006, at which time they pay semi-annual interest only until maturity on April 1, 2010 and are convertible into 2,798,853 shares of common stock at the option of the holder.



The senior secured convertible notes totaling $1,259,224 include interest accrued thereon of $141,574, are secured by a first priority security interest in essentially all of the Company's assets, are equal in rank with other senior debt and accrue interest at 8% until October 1, 2006 and thereafter pay semi-annual interest only until maturity at either April 1 or October 1, 2010. In the aggregate the senior convertible notes are convertible into 107,848,128 shares of Common Stock at the option of the holders.



K.  RELATED PARTY TRANSACTIONS

Under the terms of a security agreement between the Company and its Chief Executive Officer (the "Executive"), each and all of the Company's debts, obligations and liabilities to the Executive now existing or hereafter created, incurred, assumed or guaranteed are secured by a first priority lien on all of the Company's assets, which lien was perfected on July 16, 2002, and are equal in rank with other senior debt.



On June 16, 2006 the Company entered into a Letter Agreement (the "Agreement") with James R. Arabia, the Company's President and Chief Executive Officer, whereby Mr. Arabia shall be entitled to receive shares and cash in consideration of an aggregate of $542,137 owed by the Company to Mr. Arabia (the "Past Due Amount"). The Past Due Amount consists of (i) accrued salary and benefits, (ii) advances made to the Company by Mr. Arabia, and (iii) amounts due pursuant to senior secured notes with an aggregate face value of $200,000 held by Mr. Arabia.



Pursuant to the Agreement, the Company and Mr. Arabia agreed to the following:



|· | In consideration of $112,500 of the Past Due Amount, Mr. Arabia is entitled to receive 75,000,000 shares of the Company's common stock, subject to a beneficial ownership limitation of 29%, or 20% on a fully diluted basis. Mr. Arabia is currently the beneficial owner of approximately 29.6% of the Company's common stock, or 20.2% on a fully-diluted basis (accordingly, pursuant to the beneficial ownership limitation, Mr. Arabia is not entitled to the issuance of any portion of the 75,000,000 shares as of the date of the Agreement); and
|- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|· | Mr. Arabia shall forgive $112,500 of the Past Due Amount; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|· | $317,137 of the Past Due Amount is to be paid to Mr. Arabia in cash in minimum monthly installments of $20,000.                                                                                                                                                                                                                                                                                                                                                                                                                                           

At June 30, 2007 the Company's Due to Balance owed to its Chief Executive Officer was $257,363. The Company also owes the Executive $ 597,714 pursuant to various senior secured notes, including interest thereon as follows: (i) $216,441 of senior secured notes due on March 30, 2006, and (ii) senior secured convertible notes totaling $381,273.



In September 2006 the Company converted a secured convertible note with a face value of  $6,000 held by its Chief Financial Officer, Robert T. Malasek, into 2,548,533 shares and granted a stock bonus in the amount of 2,500,000 restricted shares valued at $2,500

- 29 -



|
|





L.  COMMITMENTS AND CONTINGENCIES



Insurance



Currently the Company does not carry product liability insurance. Pending the maturity of the Company's new marketing strategy, and sales volume that the Company determines warrants the need for insurance, coverage will be evaluated in amounts that management believes is adequate to cover the risks it faces in the industry in which it competes. There can be no assurance, however, that the Company can afford such insurance coverage or that such insurance coverage will be adequate to cover all losses, which the Company may incur in future periods or that coverage will be available for all of the types of claims the Company faces or may face. We cannot assure the safety or effectiveness of our products.



Unsecured Creditors of the Company



As of June 30, 2007 the Company maintains a litigation reserve of $125,795 for the payment of past due unsecured creditors for which it does not have a defined payment arrangement (including creditors whose debts were extinguished due to the statute of limitations expiring for such creditors to take legal action to collect their debt - see also Note R "Other Income"). Additionally, the Company is in payment default on two unsecured notes totaling $75,072, including interest thereon of $17,120 which accrue interest at the rate of 8% per annum. Whenever feasible the Company negotiates with these creditors to reach settlement agreements that are acceptable to the Company, including agreements to swap equity for debt owed to these creditors. However, if the Company is unable to reach acceptable settlement arrangements it may be subject to various collection actions.



Employment Contracts



Effective July 1, 2004 the Company and its Chief Executive Officer, James R. Arabia, entered into an amended employment contract (the "Amended and Restated Employment Contract") which provides the following to Mr. Arabia; (i) Base salary of $250,000, (ii) bonus, if any, determined and payable at the discretion of the board of directors, (iii) $6,000 annual car allowance, and (iv) complete medical coverage. Under the Amended and Restated Employment Contract if the Company terminates the Mr. Arabia without cause, or if he terminates his employment for good reason, the Company is obligated to make a lump sum severance payment equal to one year's base salary. Additionally, commencing on the first day after the date of the Amended and Restated Employment Contract and on each day thereafter, the period of employment for Mr. Arabia covered by the agreement shall be extended for one (1) additional day so that a constant one (1) year employment period shall be in effect.



Litigation and Legal Proceedings



At June 30, 2007 the Company has a litigation reserve totaling $125,795 which it maintains for legal and settlement costs associated with its restructuring efforts and for current litigation arising in the ordinary course of business. Notwithstanding the litigation reserve established, in the light of the Company's current financial condition, the Company's cash liability, if any, arising from legal proceedings, could have a material adverse effect on the Company's financial position, results of operations or cash flows.



Required Stock Payments



The Company has obligations to issue restricted shares of common stock as payment for services which total, in the aggregate, 407,355,689 shares as follows; 75,000,000 shares to the Company's Chief Executive Officer, James R. Arabia, as settlement of a portion of monies owed to Mr. Arabia, 332,355,689 shares to Dutchess as an incentive payment for making $2,348,500 of loans to the Company. Issuance of shares to Mr. Arabia may only occur at a time and in an amount that would not result in such issuance having the effect of causing his beneficial ownership of the Company to exceed either 29% or 20% on a fully diluted basis. Issuance of shares to Dutchess may only occur at a time and in an amount that would not result in such issuance having the effect of causing their beneficial ownership to exceed 4.75%. As a result of these obligations, if the Company issues stock to parties other than Mr. Arabia or Dutchess its obligation to issue additional stock to these parties is triggered, thereby amplifying the dilutive effect of future issuances of stock.

- 30 -



|
|





Required Payments to Guarantor

In March of 2006 the Company concluded an offering of senior secured convertible notes (the "Senior Convertible Notes") after having raised a total of $417,500 under the offering (the stated size of the offering was $1,250,000). Investors were offered a third-party guaranty as to the timely payment of principal and interest on the Senior Convertible Notes, The entire $417,500 raised was covered by the third-party guaranty (the "Guaranty Agreement"). The Guaranty Agreement was entered into by the Company and Milan Mandaric (the "Guarantor") for the express benefit of any investor that purchased a Senior Convertible Note. It requires that the Guarantor unconditionally and irrevocably and without limitation or exception (other than conditions, limitations or exceptions specifically described in the Guaranty Agreement) guaranty the faithful and complete payment of any sums, including principal and interest, contemplated by any Senior Convertible Note as required by the Guaranty Agreement. The Company is permitted to enforce the Guaranty on behalf of purchasers of the Senior Convertible Notes. Additionally, should the Guarantor be required to make any payments under the Guaranty Agreement to or for the benefit of holders of the Senior Convertible Notes pursuant to his obligations under the Guaranty the Company shall be obligated to repay Guarantor for all such payments and advances, and shall also be obligated to repay any reasonable fees and expenses, including legal expenses, expended by Guarantor in defending against any unsuccessful attempt by any party to enforce the Guaranty (unless such fees are paid by the losing party). The repayment of all such advances, payments and fees and expenses shall be secured by a first priority lien on essentially all of the Company's assets and will be equal in priority with all other senior secured debt of the Company and will accrue interest at the annual rate of eight percent (8%) and shall be due in full and payable on October 1, 2008.



At June 30, 2007 $297,500 of the Senior Convertible Notes remained outstanding ; $ 97,500 face value of the Senior Convertible Notes have a conversion price of $.025 per share, $100,000 face value has a conversion price equal to the greater of (i) the amount of shares determined by dividing the aggregate principal amount being tendered for conversion including interest accrued thereon by the conversion price in effect at the time of such conversion (the initial Conversion Price shall be equal to $.03125), or (ii) the amount of shares determined by multiplying by .05% the total amount of shares of Common Stock outstanding as of the date that the Company receives a written notice from the holder of their desire to convert for each $5,000 principal amount being tendered for conversion, and $100,000 face value has a conversion price equal to the amount of shares determined by multiplying by .05% the total amount of shares of Common Stock outstanding as of the date that the Company receives a written notice from the holder of their desire to convert for each $5,000 principal amount being tendered for conversion. Of the $297,500 outstanding, $65,000 pay interest of 8% per annum on a quarterly basis and mature on October 1, 2008, $17,500 pay interest of 10% per annum on a quarterly basis and mature on October 1, 2008 $15,000 accrues interest at the rate of 6% per annum and matures on October 1, 2008 and $200,000 pay interest of 14% per annum on a quarterly basis and mature on October 1, 2009.



At June 30, 2007 the Guarantor had made principal and interest payments pursuant to the Guaranty Agreement totaling $130,717 that resulted in the retirement of $120,000 face value of Senior Convertible Notes and the issuance of senior secured notes to the Guarantor having an aggregate face value of $130,717 as reimbursement for the Guarantor's payments made pursuant to the Guaranty.



M.  STOCK ISSUANCES:



For the year ended June 30, 2007 the Company issued; (i) 43,000,000 restricted shares of common stock for $86,600 of services rendered, (ii) 1,705,839 restricted shares of common stock for payment of an incentive fee valued at $6,823, (iii) 8,920,533 restricted shares of common stock for the conversion of debt valued at $22,251, and (iv) 414,140,994 shares of common stock for cash proceeds of $569,839.



N.  INCOME TAXES:



As of June 30, 2007, the Company had net operating loss carry-forwards totaling approximately $26,584,017, before any limitations. The carry-forwards expire through 2027.

The realization of any future income tax benefits from the utilization of net operating losses may be severely limited. Federal and state tax laws contain complicated change of control provisions (generally when a more than 50 percent ownership change occurs within a three-year period), which, if triggered, could limit or eliminate the use of the Company's net operating loss carry-forwards.



O.  MAJOR CUSTOMER AND SEGMENT INFORMATION



The Company operates solely in one industry segment: the marketing and support of its homeopathic drug used for the treatment and prevention of migraine headaches. The Company has no customers that exceed 5% of gross revenues for the year ending June 30, 2007. The Company has no operations or assets located outside of the United States. The Company's sales are concentrated in the MigraSpray product, creating a risk of concentration associated with the sale of a single product and limited customer base. The loss of this single product market could cause severe damage to the Company's financial future.

- 31 -



|
|





P.  RESTRUCTURING



As of June 30, 2007 the Company maintains a litigation reserve of $125,795 for the payment of past due unsecured creditors for which it does not have a defined payment arrangement (including creditors whose debts were extinguished due to the statute of limitations expiring for such creditors to take legal action to collect their debt - see also Note R "Other Income"). Additionally, the Company is in payment default on two unsecured notes totaling $75,072, including interest thereon of $17,120 which accrue interest at the rate of 8% per annum. Whenever feasible the Company negotiates with these creditors to reach settlement agreements that are acceptable to the Company, including agreements to swap equity for debt owed to these creditors. However, if the Company is unable to reach acceptable settlement arrangements it may be subject to various collection actions.



As of June 30, 2007, the Company was in payment default on the following secured notes; (i) six senior notes issued to Dutchess totaling $2,069,762, before aggregate original issue discounts of $278,299, including interest accrued thereon of $87,041, which accrue interest at the rate of 12%,  (ii) five senior secured notes totaling $443,143, including interest thereon of $57,915 which accrue interest at the rate of between 4% and 8%, and (iii) subordinated secured notes totaling $1,662,384 including interest thereon of $498,796 which accrue interest at the rate of between 8% and 10%. All of the defaulted notes listed have either passed their original stated maturity or are entitled to accelerated payment of principal under the default provisions of such notes. None of the holders of the defaulted notes discussed herein have initiated any collection actions against the Company.



The Company has no scheduled repayment arrangements in regard to any of the defaulted debt listed above except in regard to $200,000 (face value) of the senior secured notes which are owned by the Company's Chief Executive Officer, James R. Arabia, pursuant to an agreement reached between the Company and Mr. Arabia on June 16, 2006 whereby the Company makes monthly payments against past due monies owed to Mr. Arabia, of which the $200,000 of senior notes is included in such past due monies owed (see also Note K to the Financial Statements - "Related Party Transactions" and Note L to the Financial Statements - "Commitments and Contingencies").



Because these creditors are secured by virtually all of the Company's assets, the Company could face action to have its assets foreclosed upon. Collection action by any secured creditor is governed by an Intercreditor Agreement between such creditors, which requires a majority of senior creditors to approve of any collection action by any secured creditor(s) before such action is commenced (including an action to foreclose on the Company's assets). Although the Company believes that the majority of senior creditors will not agree to authorize collection action at this time, there can be no assurance that the senior creditors will not authorize certain collection actions. If collection actions are authorized and do commence, the assets of the Company could be foreclosed upon and the Company's ability to continue as a going concern would be severely limited.



It is likely that the Company will attempt to negotiate debt for equity swaps with certain defaulted creditors, which could lead to the issuance of substantial amounts of common stock and substantial dilution of then-existing shareholders. There can be no assurance that any of the Company's secured creditors will accept equity in exchange for their debt. If the Company is unable to issue equity to retire much of its secured debt obligations, it may be very difficult to raise capital through the sale of debt or equity.

The Company believes that securing adequate working capital through its capital raising efforts is an integral part of its restructuring. On March 31, 2006 the Company entered into an Investment Agreement with Dutchess Private Equities Fund, II, L.P. ("Dutchess"). Pursuant to the Agreement, Dutchess committed to purchase up to $10,000,000 of the Company's common stock over the course of 36 months in installments that may occur as frequently as every seven 7 days (in the Company's discretion) and the Company obligated itself to file a registration statement with the Securities and Exchange Commission ("SEC") covering the shares of common stock underlying the Investment Agreement (2,000,000,000 shares) and to use its reasonable efforts to have the registration statement declared effective by the SEC.



On May 5, 2006 the SEC declared the Registration Statement effective for the shares underlying the Investment Agreement thereby entitling the Company to request that Dutchess purchase its common stock as outlined in the Agreement. The amount the Company may request from each purchase ("Puts"), shall be equal to, at its election, either (i) $150,000 or; (ii) 200% of the average daily volume (U.S. market only) ("ADV") of the Company's common stock for the ten (10) trading days prior to the applicable put notice date, multiplied by the average of the 3 daily closing bid prices immediately preceding the put date. The Company may tender a Put to Dutchess as often as once every 7 days and the put date shall be the date that Dutchess receives a put notice of a draw down by the Company. The purchase price shall be set at 95% of the lowest closing highest posted bid price of the common stock during the pricing period. The pricing period shall be the five (5) consecutive trading days immediately after the put date. As of June 30, 2007 the Company had tendered three (50) Puts to Dutchess, which in the aggregate, resulted in the sale of 414,376,245 shares of registered stock and net proceeds to the Company of $ 576,488.

- 32 -



|
|





In addition to its Put rights under the Investment Agreement, the Company also secured the following loans from Dutchess in the form of promissory notes; a first note in the amount of $600,000 on May 16, 2006, which resulted in $460,000 of net proceeds to the Company, a second note in the amount of $201,500 on August 14, 2006, which resulted in net proceeds of $140,000 to the Company, a third note in the amount of $403,000 on September 18, 2006, which resulted in net proceeds to the Company of $285,000 ,a fourth note in the amount of 572,000 on December 15, 2006 which resulted in $400,000 of net proceeds to the Company, a fifth note in the amount of 429,000 on March 22, 2007 which resulted in $300,000 of net proceeds to the Company, and a sixth note in the amount of $143,000 on June 1, 2007 which resulted in $100,000 of net proceeds to the Company. Under the terms of the notes the Company must repay Dutchess in monthly installments in an amount equal to the greater of $186,949 per month or 100% of the proceeds of all Puts tendered to Dutchess within a thirty day period. The note is senior secured debt of the Company, equal in rank with all other senior secured debt, and is further secured by 50 Put notices that the Company executed and tendered to Dutchess as collateral for the note. Since June of 2006 the Company has been unable to meet the minimum monthly payments required under the notes. Dutchess receives 100% of the proceeds of all Puts tendered by the Company and has not exercised or given notice of its intention to exercise any rights or remedies available to them under the terms of the notes. The note is senior secured debt of the Company, equal in rank with all other senior secured debt, and is further secured by 50 Put notices that the Company executed and tendered to Dutchess as collateral for the note.



There can be no assurance that the Company will timely complete either its financing efforts or other aspects of its restructuring, or that its financing proceeds will be adequate to meet its working capital needs, or that if its restructuring goals are reached cash flows will be sufficient to fund the Company's ongoing capital and operating needs. If the Company is unable to complete a successful restructuring, including its financing efforts, the Company will be severely limited in its ability to execute its contemplated business plan and continue as a going concern.



Q.  GOING CONCERN:



To date the Company has had limited sales due to the early stage of its efforts to transition into the marketing and distribution of its products. Prior to the first quarter of fiscal year ending June 30, 2002, the Company was primarily engaged in research and development activities. Consequently, the Company has incurred recurring losses from operations. These factors, as well as the risks associated with raising capital through the issuance of equity and/or debt securities creates uncertainty as to the Company's ability to continue as a going concern.



The Company's plans to address its going concern issues include:



|* | Increasing sales of its products through national distribution channels and through direct marketing to consumers;     
|- | -----------------------------------------------------------------------------------------------------------------------
|* | Raising capital through the sale of debt and/or equity securities; and,                                                
|* | Settling outstanding debts and accounts payable, when available, through the issuance of debt and/or equity securities.

There can be no assurance that the Company will be successful in its efforts to increase sales, issue debt and/or equity securities for cash or as payment for outstanding obligations.

Capital raising efforts may be influenced by factors outside of the control of the Company, including, but not limited to, capital market conditions. During the year ended June 30, 2007 the Company raised cash and retired outstanding obligations through the issuance of equity and debt securities totaling $1,842,475 in the aggregate. Of this amount, $6,375 of equity securities were issued to pay past due creditors.



The Company is in various stages of development on a number of products and is actively attempting to market its migraine relief product nationally. As a result of capital constraints the national marketing of its migraine relief product has been very limited, and the Company has experienced slow sales to date. The Company believes its ability to build upon the current sales levels is enhanced by (i) the efficacy of its migraine product, MIGRASPRAY, as demonstrated by clinical trial results, (ii) the addition of new management, (iii) the implementation of the Company's marketing strategy, and (iv) continued growth of it's distribution platform.



R.  OTHER INCOME:



In fiscal year ending June 30, 2006 the Company recognized substantial amounts of other income, which is primarily comprised of non-recurring transactions as follows:



For the fiscal year ending June 30, 2006 the Company recognized other income of $161,528, which is comprised of; (i) $43,500 associated with discounted settlements of various accounts payable, (ii) a reduction of $588of accrued interest due to Officers of the Company as a result of the Officers forgiving such accrued interest, (iii) a reduction of $112,500 of accrued salaries and benefits due to the Company's Chief executive Officer, James R. Arabia, as a result of Mr. Arabia forgiving such accrued salary and benefits, and (iv) $4,940 derived from interest income from a note receivable.

For the fiscal year ending June 30, 2007 the Company recognized other income comprised entirely of the extinguishment of debt that the Company wrote off due to the fact that the statute of limitations had expired for the parties to take legal action to collect on such debt.

- 33 -



|
|





ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING WITH FINANCIAL DISCLOSURE.



None



ITEM 8A.  CONTROLS AND PROCEDURES.



(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. There was no change to our internal controls or in other factors that could affect these controls during the period covered by this report  that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



(b) Limitations on Effectiveness of Disclosure Controls and Procedures



Disclosure controls and procedures cannot provide absolute assurance of achieving financial reporting objectives because of their inherent limitations. Disclosure controls and procedures is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Disclosure controls and procedures also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by disclosure controls and procedures. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.



PART III



ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT



DIRECTORS AND EXECUTIVE OFFICERS



The following table sets forth certain information such as the name, age, and current position(s) of each director and executive officer of the Company.



|Name                   | Age | Position                                        
|---------------------- | --- | ------------------------------------------------
|                       |     |                                                 
|James R. Arabia        | 50  | Chairman, President, and Chief Executive Officer
|                       |     |                                                 
|Robert T. Malasek      | 39  | Chief Financial Officer, Treasurer and Secretary
|                       |     |                                                 
|Timothy R. Scott, PhD. | 55  | Director                                        
|                       |     |                                                 
|John W. Huemoeller     | 51  | Director                                        

JAMES R. ARABIA



Mr. Arabia assumed the role of Chairman of the Board of Directors in January 2002, and became President and Chief Executive Officer of the Company during September 2001 and Chief Financial Officer in May of 2005. From February 1997 through June 2000, Mr. Arabia served as Chairman, Chief Executive Officer and President of ICH Corporation, an American Stock Exchange listed company. During Mr. Arabia's tenure, ICH grew from a non-operational company to becoming the parent company of various subsidiaries that owned and operated 265 fast food and family dining restaurants, generating approximately $245 million in revenues and employing approximately 7,800 people. From 1982 through 1997, Mr. Arabia provided financial advisory and investment banking services to a variety of private clients.

- 34 -



|
|





ROBERT T. MALASEK



Effective August 15, 2006 the Company re-appointed Robert T. Malasek to serve as its Chief Financial Officer and Secretary. Mr. Malasek had previously served as Controller for the Company from September of 2001 until October of 2002 at which time he began serving as Chief Financial Officer and Secretary until his resignation in May of 2005. From May 2005 until the present Mr. Malasek has rendered accounting consulting services to a variety of clients (including the Company), including a number of public companies. From September 1987 until August 1999 Mr. Malasek was employed with Starwood Hotel & Resorts Worldwide, Inc. in a number of positions within the accounting department and became Assistant Controller in 1998 until his departure in 1999. Mr. Malasek received his Bachelor of Science in Accountancy from San Diego State University in 1998.



TIMOTHY R. SCOTT, PHD



Dr. Scott has served on the Board of Directors since September 2001. From April 1998 to June 2000, Dr. Scott served as a member of the Board of Directors of ICH Corporation, and as a member of ICH's compensation committee. Dr. Scott also serves as President and Senior Pastor of a 1,200-member church located in San Diego, California and hosts a radio talk show called "Dr. Scott Live." Dr. Scott received his Ph.D. in theology from Christian University in 1981, and served as a professor of philosophy and religion at Pacific International College from 1981 to 1985.



JOHN W. HUEMOELLER



Mr. Huemoeller has served on the Board of Directors since July of 2003. Mr. Huemoeller is the CEO and founder of Humware Media Corp. ("Humware"), a company engaged in publishing and diversified sports media. Prior to forming Humware in 1996 Mr. Huemoeller spent approximately 14 years in the securities industry as a registered representative and registered principal.



All members of the Board of Directors are elected to serve until their respective successors for the Class (as defined below) have been elected and qualified or until their earlier death, resignation or removal in the manner specified in the Company's by-laws. The Board of Directors is divided into three classes, with the term of office of the first class to expire at the first annual meeting of stockholders following such classification ("Class 1 Directors") and the term of office of the second class to expire at the second annual meeting following such classification ("Class 2 Directors") and the term of office of the third class to expire at the third annual meeting following such classification ("Class 3 Directors"). The three classes of directors shall be as nearly equal in number as possible. At each annual meeting of stockholders following such initial classification, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Both Mr. Huemoeller and Dr. Scott are Class 1 Directors, Mr. Arabia is a Class 2 Director. There are currently no Class 3 directors.



- 35 -



|
|





ITEM 10.  EXECUTIVE COMPENSATION



SUMMARY OF CASH AND CERTAIN OTHER COMPENSATION



The following table shows, for the most recent three fiscal years, the cash compensation paid by the Company, as well as all other compensation paid or accrued for those years to the Chief Executive Officer and the Company's other executive officers as of June 30, 2007.



|SUMMARY COMPENSATION TABLE                                                           |                                                                            
|------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------
|                                                                                     |                                                                            
|                                                                                     |                                                                            
|Name and Principal Position                                                          | Fiscal Year                                                                
|                                                                                     |                                                                            
|James R. Arabia
Chief Executive Officer                                              | 2006                                                                       
|2005                                                                                 | $250,000(1)(2)                                                             
|2004                                                                                 | 164,640(1)(2)                                                              
|                                                                                     |                                                                            
|Robert T. Malasek
Former Chief Financial
Officer (current CFO as
of August 15, 2006) | 2006                                                                       
|2005                                                                                 | -                                                                          
|2004                                                                                 | 45,000                                                                     
|                                                                                     |                                                                            
|                                                                                     |                                                                            
|                                                                                     |                                                                            
|(1)                                                                                  | Accrued but not paid.                                                      
|(2)                                                                                  | Subsequently waived by Executive.                                          
|(3)                                                                                  | Other income earned by Mr. Malasek as an outside consultant to the Company.

The following table represents the options granted to the Named Executive Officers in the last fiscal year and the value of such options.



OPTION GRANTS IN LAST FISCAL YEAR



|                  |                                                                                             | Realized
Assumed
Rates
of Stock
Appreciation
for
Term 10%($) |  | Options
Granted(#) |  | Number of
Securities
Underlying
in Fiscal
Year |  | Individual
Grants
% if Total
Options
Granted to
Employees
Base
Price($/SH) |  | Exercise
or
Expiration
Date |  | Potential
Value of
Annual
Price
Option
5%($)
|----------------- | ------------------------------------------------------------------------------------------- | ------------------------------------------------------------ |  | ------------------ |  | ---------------------------------------------- |  | -------------------------------------------------------------------------- |  | --------------------------- |  | --------------------------------------------
|                  |                                                                                             |                                                              |  |                    |  |                                                |  |                                                                            |  |                             |  |                                             
|James R. Arabia   | (1)                                                                                         | $   -                                                        |  | -                  |  | 0.0%                                           |  | $   -                                                                      |  | N/A                         |  | $   -                                       
|Robert T. Malasek | (1)                                                                                         | $   -                                                        |  | -                  |  | 0.0%                                           |  | $   -                                                                      |  | N/A                         |  | $   -                                       
|                  |                                                                                             |                                                              |  |                    |  |                                                |  |                                                                            |  |                             |  |                                             
|                  |                                                                                             |                                                              |  |                    |  |                                                |  |                                                                            |  |                             |  |                                             
|                  |                                                                                             |                                                              |  |                    |  |                                                |  |                                                                            |  |                             |  |                                             
|(1)               | There were no option grants during the year ending June 30, 2007 or subsequent to year-end.

- 36 -



|
|





Option Holdings

The following table represents certain information with respect to options held by the Named Executive Officers.



FISCAL YEAR-END OPTION VALUES



|                  |                                                                  |             | Number of Securities
Underlying Unexercised
Options at Fiscal Year-End (#) |               | Value of Unexercised
In-the-Money Options
at Fiscal Year-End ($)
|----------------- | ---------------------------------------------------------------- | ----------- | -------------------------------------------------------------------------- | ------------- | ----------------------------------------------------------------
|                  |                                                                  |             |                                                                            |               |                                                                 
|Name              |                                                                  | Exercisable |                                                                            | Unexercisable |                                                                 
|                  |                                                                  |             |                                                                            |               |                                                                 
|                  |                                                                  |             |                                                                            |               |                                                                 
|James R. Arabia   | (1)                                                              |             | -                                                                          |               | -                                                               
|Robert T. Malasek | (1)                                                              |             | -                                                                          |               | -                                                               
|                  |                                                                  |             |                                                                            |               |                                                                 
|                  |                                                                  |             |                                                                            |               |                                                                 
|                  |                                                                  |             |                                                                            |               |                                                                 
|(1)               | There were no options being held by any Named Executive Officer.



COMPENSATION OF DIRECTORS



All director fees have been accrued and no director has received to date cash compensation for his services as a director. All directors are entitled to be reimbursed for travel and other expenses incurred while attending meetings of the Board of Directors.



|NAME                  |                                                                                                                                                      | FISCAL
YEAR
ISSUED |  | Director fees |  | # OF SHARES |  | $ VALUE OF
GRANT
|--------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------ |  | ------------- |  | ----------- |  | ----------------
|                      |                                                                                                                                                      |                    |  |               |  |             |  |                 
|Timothy R. Scott, PhD |                                                                                                                                                      | 2006               |  | $12,000       |  | -           |  | -               
|                      |                                                                                                                                                      | 2005(1)            |  | $ 6,500       |  | -           |  | -               
|                      |                                                                                                                                                      | 2004(2)            |  | $ (12,167)    |  | -           |  | -               
|                      |                                                                                                                                                      |                    |  |               |  |             |  |                 
|John W. Huemoeller    |                                                                                                                                                      | 2006               |  | $ 9,000       |  | -           |  | -               
|                      |                                                                                                                                                      | 2005(1)            |  | $ 6,500       |  | -           |  | -               
|                      |                                                                                                                                                      | 2004(2)            |  | $  (3,750)    |  | -           |  | -               
|                      |                                                                                                                                                      |                    |  |               |  |             |  |                 
|                      |                                                                                                                                                      |                    |  |               |  |             |  |                 
|                      |                                                                                                                                                      |                    |  |               |  |             |  |                 
|(1)                   | Accrued but not paid.                                                                                                                               
|(2)                   | The negative incomes shown for 2004 reflect the fact that Dr. Scott and Mr. Huemoeller waived director fees that had been accrued in previous years.

EMPLOYMENT CONTRACTS



James R. Arabia, Chairman, President, and Chief Executive Officer



Effective July 1, 2004 the Company and its Chief Executive Officer, James R. Arabia, entered into an amended employment contract (the "Amended and Restated Employment Contract") which provides the following to Mr. Arabia; (i) Base salary of $250,000, (ii) bonus, if any, determined and payable at the discretion of the board of directors, (iii) $6,000 annual car allowance, and (iv) complete medical coverage. Under the Amended and Restated Employment Contract if the Company terminates the Mr. Arabia without cause, or if he terminates his employment for good reason, the Company is obligated to make a lump sum severance payment equal to one year's base salary. Additionally, commencing on the first day after the date of the Amended and Restated Employment Contract and on each day thereafter, the period of employment for Mr. Arabia covered by the agreement shall be extended for one (1) additional day so that a constant one (1) year employment period shall be in effect.



- 37 -



|
|





ITEM 11.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT



PRINCIPAL STOCKHOLDERS



The following table sets forth information with respect to the beneficial ownership of Common Stock, as of June 30, 2007 (assuming the exercise of options, issuance of stock grants, the conversion of convertible debt or preferred stock with underlying common stock conversion rights, and warrants that are exercisable within 60 days of the date hereof) by:



(i) each person known to the Company to beneficially own more than 5 percent of the outstanding shares of Common Stock, (ii) each of the Company's directors, (iii) each of the Company's executive officers named in the Summary Compensation Table above, and (iv) all directors and officers of the Company as a group. Unless otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all the shares beneficially owned, subject to community property laws, where applicable. Percentage ownership assumes all warrants and options of listed person exercised and all other warrant and options unexercised.





|Name and Address                                                                            |  | Common Stock beneficially owned (1) |  | Percent of Common Stock beneficially owned (1)
|------------------------------------------------------------------------------------------- |  | ----------------------------------- |  | ----------------------------------------------
|                                                                                            |  |                                     |  |                                               
|James R. Arabia (2)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101         |  | 85,865,325                          |  | 13.0%                                         
|                                                                                            |  |                                     |  |                                               
|Financial Acquisition Partners, LP (3)
4019 Goldfinch Street, Suite 474
San Diego, CA 92103 |  | 15,750,000                          |  | 2.6%                                          
|                                                                                            |  |                                     |  |                                               
|Lowell Blankfort (4)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101        |  | 26,415,055                          |  | 4.2%                                          
|                                                                                            |  |                                     |  |                                               
|AK Trust. (5)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101               |  | 33,652,795                          |  | 5.3%                                          
|                                                                                            |  |                                     |  |                                               
|Robert T Malasek
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101            |  | 6,348,533                           |  | 1.1%                                          
|                                                                                            |  |                                     |  |                                               
|Timothy R. Scott, PhD (6)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101   |  | 4,220,560                           |  | 0.7%                                          
|                                                                                            |  |                                     |  |                                               
|John W. Huemoeller (7)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101      |  | 3,164,815                           |  | 0.5%                                          
|                                                                                            |  |                                     |  |                                               
|Milan Mandaric (8)
c/o NatureWell, Inc.
110 W C St. Suite 1300
San Diego, CA 92101          |  | 20,950,309                          |  | 3.4%                                          
|                                                                                            |  |                                     |  |                                               
|All directors and executive officers as a group (four individuals)                          |  | 99,599,233                          |  | 14.9%                                         
|                                                                                            |  |                                     |  |                                               
|                                                                                            |  |                                     |  |                                               
|                                                                                            |  |                                     |  |                                               

- 38 -



|
|







|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|1. | Applicable percentage ownership is based on 603,933,318 shares of Common Stock outstanding as of June 30, 2007, together with securities exercisable or convertible into shares of Common Stock within 60 days of June 30, 2007 for each stockholder. Includes shares of common stock underlying convertible securities. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities                                                                                                                                                                                                  
|2. | Includes the following securities: (i) 1,875,000 shares of common stock underlying 75 shares of Series C Convertible Preferred Stock; (ii) 5,750,000 shares of common stock held by Financial Acquisition Partners, LP ("FALP"), a partnership for which Mr. Arabia is the sole General Partner. Mr. Arabia claims sole investment and voting power with regard to the 5,750,000 shares; (iii) 54,077,582 shares of common stock underlying senior secured convertible notes with a face value of $360,000; (iv) 9,000,000 shares of Series A Common Stock; (v) 10,000,000 shares of Series A Common Stock held by FALP. Mr. Arabia claims sole investment and voting power with regard to the 10,000,000 shares.
|3. | Includes 10,000,000 shares of Series A Common Stock.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|4. | Includes 21,643,626 shares of common stock underlying convertible notes with an aggregate face value of $222,500 owned by Mr. Blankfort in either the Blankfort Trust or Blankfort Unlimited, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|5. | Includes 26,123,435 shares of common stock underlying convertible notes with an aggregate face value of $87,500.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
|6. | Includes 4,220,560 shares of common stock underlying a convertible note with a $10,000 face value.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|7. | Includes 3,164,815 shares of common stock underlying a convertible note with a face value of $7,500.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|8. | Includes 20,950,309 shares of common stock underlying senior secured convertible notes with a face value of $11,150.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             



ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Under the terms of a security agreement between the Company and its Chief Executive Officer (the "Executive"), each and all of the Company's debts, obligations and liabilities to the Executive now existing or hereafter created, incurred, assumed or guaranteed are secured by a first priority lien on all of the Company's assets, which lien was perfected on July 16, 2002, and are equal in rank with other senior debt.



On June 16, 2006 the Company entered into a Letter Agreement (the "Agreement") with James R. Arabia, the Company's President and Chief Executive Officer, whereby Mr. Arabia shall be entitled to receive shares and cash in consideration of an aggregate of $542,137 owed by the Company to Mr. Arabia (the "Past Due Amount"). The Past Due Amount consists of (i) accrued salary and benefits, (ii) advances made to the Company by Mr. Arabia, and (iii) amounts due pursuant to senior secured notes with an aggregate face value of $200,000 held by Mr. Arabia.

Pursuant to the Agreement, the Company and Mr. Arabia agreed to the following:

|● | In consideration of $112,500 of the Past Due Amount, Mr. Arabia is entitled to receive 75,000,000 shares of the Company's common stock, subject to a beneficial ownership limitation of 29%, or 20% on a fully diluted basis. Mr. Arabia is currently the beneficial owner of approximately 29.6% of the Company's common stock, or 20.2% on a fully-diluted basis (accordingly, pursuant to the beneficial ownership limitation, Mr. Arabia is not entitled to the issuance of any portion of the 75,000,000 shares as of the date of the Agreement); and
|- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|● | Mr. Arabia shall forgive $112,500 of the Past Due Amount; and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
|● | $317,137 of the Past Due Amount is to be paid to Mr. Arabia in cash in minimum monthly installments of $20,000.                                                                                                                                                                                                                                                                                                                                                                                                                                           

PREFERRED STOCK



The Company has outstanding 75 shares, $1,000 liquidation preference, of Series C Convertible Preferred Stock. Pursuant to the terms of the Series C Convertible Preferred stock, owned by James R. Arabia, Chairman, President, And Chief Executive Officer of the Company, Mr. Arabia is allowed to cast a vote, on all matters that the Company's shareholders are permitted to vote upon, equal to .7% of all outstanding securities that are eligible to vote at the time of such shareholder action for each share of Series C Convertible Preferred that he owns (.7% X 75 shares = 52.5% of total vote). The shares convert into 1,875,000 shares of the Company's common stock and are non-transferable without the consent of the board of directors.



ITEM 13.  EXHIBITS



| | (a) | The following documents are filed as part of this report:
| | --- | ---------------------------------------------------------
| |     | 1.                                                       
| |     | 2.                                                       



- 39 -



|
|





EXHIBIT INDEX



|EXHIBITNUMBER |                                                                                                                            | DESCRIPTION                                                                                                                                                                                                                                                              
|------------- | -------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|4.1**         |                                                                                                                            | 2004 Incentive Stock Bonus and Option Plan                                                                                                                                                                                                                               
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.1******    |                                                                                                                            | Morgan & Sampson, Inc. Distribution Service Agreement                                                                                                                                                                                                                    
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.2*****     |                                                                                                                            | Employment Agreement for James R. Arabia.                                                                                                                                                                                                                                
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.3*****     |                                                                                                                            | Employment Agreement for Donald Brucker.                                                                                                                                                                                                                                 
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.4*****     |                                                                                                                            | Consulting Agreement for Timothy J. Connor.                                                                                                                                                                                                                              
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.5****      |                                                                                                                            | Senior Note dated October 5, 2002 in the amount of $382,500 between NatureWell, Incorporated ("Debtor") and James R. Arabia ("Holder").                                                                                                                                  
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.6****      |                                                                                                                            | Security Agreement for Senior Note dated October 5, 2002 in the amount of $382,500 between NatureWell, Incorporated ("Debtor") and James R. Arabia ("Holder").                                                                                                           
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.7*****     |                                                                                                                            | Stock Issuance Agreement for Donald Brucker with Exhibit A ("Stock Purchase Agreement"), Exhibit B ("Promissory Note") and Exhibit C ("Security Agreement").                                                                                                             
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.8*****     |                                                                                                                            | Stock Issuance Agreement for Timothy J. Connor with Exhibit A "Stock Purchase Agreement"), Exhibit B ("Promissory Note") and Exhibit C ("Security Agreement").                                                                                                           
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.9*****     |                                                                                                                            | Stock Issuance Agreement for Timothy R. Scott with Exhibit A ("Promissory Note") and Exhibit B ("Security Agreement").                                                                                                                                                   
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.10*****    |                                                                                                                            | Stock Issuance Agreement for David A. Gotz with Exhibit A ("Promissory Note") and Exhibit B ("Security Agreement").                                                                                                                                                      
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.11*****    |                                                                                                                            | Stock Issuance Agreement for Jason J. Belice with Exhibit A ("Stock Purchase Agreement"), Exhibit B ("Promissory Note") and Exhibit C ("Security Agreement").                                                                                                            
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.12*****    |                                                                                                                            | Stock Issuance Agreement for Alan S. Udin with Exhibit A ("Stock Purchase Agreement"), Exhibit B ("Promissory Note") and Exhibit C ("Security Agreement").                                                                                                               
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.13****     |                                                                                                                            | Amended and Restated Security Agreement dated September 2, 2003 with Exhibit A (January 28, 2002 Security Agreement), Exhibit B (October 5, 2002 Security Agreement).                                                                                                    
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.14****     |                                                                                                                            | Intercreditor agreement dated September 2, 2003 with Exhibit A (asset description).                                                                                                                                                                                      
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.15***      |                                                                                                                            | Term Sheet between NatureWell, Incorporated and Alan S. Udin dated November 15, 2003.                                                                                                                                                                                    
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.16***      |                                                                                                                            | Term Sheet between NatureWell, Incorporated and Timothy R. Scott dated November 15, 2003.                                                                                                                                                                                
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.17***      |                                                                                                                            | Form of Senior Note issued as part of Company Restructuring.                                                                                                                                                                                                             
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.18***      |                                                                                                                            | Form of Senior Convertible Note issued as part of Company Restructuring and Private Placement.                                                                                                                                                                           
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.19***      |                                                                                                                            | Form of Subordinate Note issued as part of Company Restructuring.                                                                                                                                                                                                        
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.20***      |                                                                                                                            | Form of Security Agreement securing Senior Notes issued as part of Company Restructuring (Security Agreement used for all debts and obligations, however incurred, payable by the Company to James R. Arabia previously reported as Exhibit 10.18 to June 30, 2003 10-K).
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.21***      |                                                                                                                            | Form of Security Agreement securing Senior Convertible Notes issued as part of Company Restructuring and Private Placement.                                                                                                                                              
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.22***      |                                                                                                                            | Form of Subordinate Security Agreement securing Subordinate Notes issued as part of Company Restructuring.                                                                                                                                                               
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.23***      |                                                                                                                            | Form of Intercreditor, Subordination and Standby Agreement used for Company Restructuring.                                                                                                                                                                               
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.24**       |                                                                                                                            | Amended and Restated Employment Contract Between NatureWell, Incorporated and James R. Arabia dated July 1, 2004.                                                                                                                                                        
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.25*        |                                                                                                                            | Guaranty Agreement.                                                                                                                                                                                                                                                      
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.26*        |                                                                                                                            | Mandaric Letter Agreement.                                                                                                                                                                                                                                               
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.27*        |                                                                                                                            | Addendum to Mandaric Letter Agreement.                                                                                                                                                                                                                                   
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.28*        |                                                                                                                            | Arabia Letter Agreement.                                                                                                                                                                                                                                                 
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.29*        |                                                                                                                            | Brucker Letter Agreement.                                                                                                                                                                                                                                                
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.30*        |                                                                                                                            | Malasek Letter Agreement.                                                                                                                                                                                                                                                
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.31*        |                                                                                                                            | Scott Letter Agreement.                                                                                                                                                                                                                                                  
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|10.32*        |                                                                                                                            | Huemoeller Letter Agreement.                                                                                                                                                                                                                                             
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|31.1          |                                                                                                                            | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith.                                                                                                                                                                       
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|31.2          |                                                                                                                            | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith.                                                                                                                                                                       
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|32.1          |                                                                                                                            | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.                                                                                                       
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|32.2          |                                                                                                                            | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.                                                                                                       
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|              |                                                                                                                            |                                                                                                                                                                                                                                                                          
|*             | Incorporated by reference to the applicable exhibits to the Company's Form 10-QSB for the period ending March 31, 2005.   
|**            | Incorporated by reference to the applicable exhibit to the Company's Form 10-KSB filed on October 14, 2004.               
|***           | Incorporated by reference to the applicable exhibits to the Company's Form 10-QSB for the period ending December 31, 2003.
|****          | Incorporated by reference to the applicable exhibit to the Company's Form 10-KSB-A filed on October 15, 2003.             
|*****         | Incorporated by reference to the applicable exhibit to the Company's Form 10-KSB filed on October 15, 2002.               
|******        | Incorporated by reference to the applicable exhibit to the Company's Form 10-KSB filed on October 15, 2001.               

- 41 -



|
|





Item 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

(1)  Audit Fees

The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for our audit of annual financial statements and review of financial statements included in our Form 10-QSBs or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was:

2007 - $22,000
2006 - $17,380

(2)  Audit-Related Fees

The aggregate fees billed in each of the last two fiscal years for assurance and related services by the principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported in the preceding paragraph:

2007 - $0
2006 - $0

(3)  Tax Fees

The aggregate fees billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning was:

2007 - $2,300
2006 - $1,000

(4)  All Other Fees

The aggregate fees billed in each of the last two fiscal years for the products and services provided by the principal accountant, other than the services reported in paragraphs (1), (2), and (3) was:

2007 - $0
2006 - $0

- 42 -



|
|





SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.







|Date:  October 12, 2007 | NATUREWELL, INCORPORATED                                                                                  
|----------------------- | ----------------------------------------------------------------------------------------------------------
|                        |                                                                                                           
|                        | By:   /s/ James R. Arabia
James R. Arabia
Chief Executive Officer, Chairman 
(Principal Executive Officer)
|                        |                                                                                                           
|                        | By:   /s/ Robert T. Malasek                                                                               
|                        | Robert T. Malasek
Chief Financial Officer
(Principal Financial and Accounting Officer)                    



In accordance with the Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.







|                                       | Title                                             | Date            
|-------------------------------------- | ------------------------------------------------- | ----------------
|                                       |                                                   |                 
|/ s /   James R. ArabiaJames R. Arabia | Chief Executive Officer
and Chairman of the Board | October 12, 2007







|                                           | Title    | Date            
|------------------------------------------ | -------- | ----------------
|                                           |          |                 
|/s/   John W. HuemoellerJohn W. Huemoeller | Director | October 12, 2007







|                                       | Title    | Date            
|-------------------------------------- | -------- | ----------------
|                                       |          |                 
|/s/   Timothy R. ScottTimothy R. Scott | Director | October 12, 2007



- 43 -



|
|